Roy S. Herbst, MD, PhD

Fernandez AI, Gavrielatou N, McCann L, Shafi S, Moutafi MK, Martinez-Morilla S, Vathiotis IA, Aung TN, Yaghoobi V, Bai Y, Chan YG, Weidler J, Herbst R, Bates M, Rimm DL. Programmed Death-Ligand 1 and Programmed Death-Ligand 2 mRNAs Measured Using Closed-System Quantitative Real-Time Polymerase Chain Reaction Are Associated With Outcome and High Negative Predictive Value in Immunotherapy-Treated NSCLC. Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer 2022, 17: 1078-1085. PMID: 35764237, DOI: 10.1016/j.jtho.2022.06.007.

Mack PC, Miao J, Redman MW, Moon J, Goldberg SB, Herbst RS, Melnick MA, Walther Z, Hirsch FR, Politi K, Kelly K, Gandara DR. Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI-Treated Patients with EGFR-Mutant NSCLC (SWOG S1403). Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2022, 28: 3752-3760. PMID: 35713632, PMCID: PMC9444942, DOI: 10.1158/1078-0432.CCR-22-0741.

Moutafi M, Martinez-Morilla S, Divakar P, Vathiotis I, Gavrielatou N, Aung TN, Yaghoobi V, Fernandez AI, Zugazagoitia J, Herbst R, Schalper KA, Rimm DL. Discovery of Biomarkers of Resistance to Immune Checkpoint Blockade in NSCLC Using High-Plex Digital Spatial Profiling. Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer 2022, 17: 991-1001. PMID: 35490853, PMCID: PMC9356986, DOI: 10.1016/j.jtho.2022.04.009.

Moutafi MK, Molero M, Martinez Morilla S, Baena J, Vathiotis IA, Gavrielatou N, Castro-Labrador L, de Garibay GR, Adradas V, Orive D, Valencia K, Calvo A, Montuenga LM, Ponce Aix S, Schalper KA, Herbst RS, Paz-Ares L, Rimm DL, Zugazagoitia J. Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small-cell lung cancer. Journal For Immunotherapy Of Cancer 2022, 10 PMID: 36002182, DOI: 10.1136/jitc-2022-004757.

Reckamp KL, Redman MW, Dragnev KH, Minichiello K, Villaruz LC, Faller B, Al Baghdadi T, Hines S, Everhart L, Highleyman L, Papadimitrakopoulou V, Neal J, Waqar SN, Patel JD, Gray JE, Gandara DR, Kelly K, Herbst RS. Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2022, 40: 2295-2306. PMID: 35658002, PMCID: PMC9287284, DOI: 10.1200/JCO.22.00912.

Hunihan L, Zhao D, Lazowski H, Li M, Qian Y, Abriola L, Surovtseva YV, Muthusamy V, Tanoue LT, Gould Rothberg BE, Schalper KA, Herbst RS, Wilson FH. RASGRF1 Fusions Activate Oncogenic RAS Signaling and Confer Sensitivity to MEK Inhibition. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2022, 28: 3091-3103. PMID: 35247929, PMCID: PMC9288503, DOI: 10.1158/1078-0432.CCR-21-4291.

Shafi S, Aung TN, Robbins C, Zugazagoitia J, Vathiotis I, Gavrielatou N, Yaghoobi V, Fernandez A, Niu S, Liu LN, Cusumano ZT, Leelatian N, Cole K, Wang H, Homer R, Herbst RS, Langermann S, Rimm DL. Development of an immunohistochemical assay for Siglec-15. Laboratory Investigation; A Journal Of Technical Methods And Pathology 2022, 102: 771-778. PMID: 35459795, PMCID: PMC9253057, DOI: 10.1038/s41374-022-00785-9.

Kim TK, Vandsemb EN, Herbst RS, Chen L. Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. Nature Reviews. Drug Discovery 2022, 21: 529-540. PMID: 35701637, DOI: 10.1038/s41573-022-00493-5.

Henick BS, Villarroel-Espindola F, Datar I, Sanmamed MF, Yu J, Desai S, Li A, Aguirre-Ducler A, Syrigos K, Rimm DL, Chen L, Herbst RS, Schalper KA. Quantitative tissue analysis and role of myeloid cells in non-small cell lung cancer. Journal For Immunotherapy Of Cancer 2022, 10 PMID: 35793873, PMCID: PMC9260844, DOI: 10.1136/jitc-2022-005025.

Peters S, Paz-Ares L, Herbst RS, Reck M. Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects. Journal For Immunotherapy Of Cancer 2022, 10 PMID: 35858709, PMCID: PMC9305809, DOI: 10.1136/jitc-2022-004863.

Herbst RS, Wang M, Chen L. When immunotherapy meets surgery in non-small cell lung cancer. Cancer Cell 2022, 40: 603-605. PMID: 35660136, DOI: 10.1016/j.ccell.2022.05.010.

Majem M, Goldman JW, John T, Grohe C, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Li S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Atagi S, Zeng L, Kulkarni D, Medic N, Tsuboi M, Herbst RS, Wu YL. Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2022, 28: 2286-2296. PMID: 35012927, DOI: 10.1158/1078-0432.CCR-21-3530.

Lopez de Rodas M, Nagineni V, Ravi A, Datar IJ, Mino-Kenudson M, Corredor G, Barrera C, Behlman L, Rimm DL, Herbst RS, Madabhushi A, Riess JW, Velcheti V, Hellmann MD, Gainor J, Schalper KA. Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer. Journal For Immunotherapy Of Cancer 2022, 10 PMID: 35649657, PMCID: PMC9161072, DOI: 10.1136/jitc-2021-004440.

Shafi S, Aung TN, Xirou V, Gavrielatou N, Vathiotis IA, Fernandez A, Moutafi M, Yaghoobi V, Herbst RS, Liu LN, Langermann S, Rimm DL. Quantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancer. Laboratory Investigation; A Journal Of Technical Methods And Pathology 2022 PMID: 35581307, DOI: 10.1038/s41374-022-00796-6.

Remon J, Lacas B, Herbst R, Reck M, Garon EB, Scagliotti GV, Ramlau R, Hanna N, Vansteenkiste J, Yoh K, Groen HJM, Heymach JV, Mandrekar SJ, Okamoto I, Neal JW, Heist RS, Planchard D, Pignon JP, Besse B. ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA. European Journal Of Cancer (Oxford, England : 1990) 2022, 166: 112-125. PMID: 35286903, DOI: 10.1016/j.ejca.2022.02.002.

Govindan R, Aggarwal C, Antonia SJ, Davies M, Dubinett SM, Ferris A, Forde PM, Garon EB, Goldberg SB, Hassan R, Hellmann MD, Hirsch FR, Johnson ML, Malik S, Morgensztern D, Neal JW, Patel JD, Rimm DL, Sagorsky S, Schwartz LH, Sepesi B, Herbst RS. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma. Journal For Immunotherapy Of Cancer 2022, 10 PMID: 35640927, PMCID: PMC9157337, DOI: 10.1136/jitc-2021-003956.

Herbst RS, Majem M, Barlesi F, Carcereny E, Chu Q, Monnet I, Sanchez-Hernandez A, Dakhil S, Camidge DR, Winzer L, Soo-Hoo Y, Cooper ZA, Kumar R, Bothos J, Aggarwal C, Martinez-Marti A. COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2022, JCO2200227. PMID: 35452273, DOI: 10.1200/JCO.22.00227.

Gettinger S, Redman MW, Herbst RS. Nivolumab Plus Ipilimumab for Previously Treated Stage IV Squamous Cell Lung Cancer-Reply. JAMA Oncology 2022, 8: 1. PMID: 35142793, DOI: 10.1001/jamaoncol.2021.7790.

Wu YL, John T, Grohe C, Majem M, Goldman JW, Kim SW, Kato T, Laktionov K, Vu HV, Wang Z, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Atasoy A, Herbst RS, Tsuboi M. Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC. Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer 2022, 17: 423-433. PMID: 34740861, DOI: 10.1016/j.jtho.2021.10.014.

Joel MZ, Umrao S, Chang E, Choi R, Yang DX, Duncan JS, Omuro A, Herbst R, Krumholz HM, Aneja S. Using Adversarial Images to Assess the Robustness of Deep Learning Models Trained on Diagnostic Images in Oncology. JCO Clinical Cancer Informatics 2022, 6: e2100170. PMID: 35271304, PMCID: PMC8932490, DOI: 10.1200/CCI.21.00170.

Hirsch FR, Redman MW, Moon J, Agustoni F, Herbst RS, Semrad TJ, Varella-Garcia M, Rivard CJ, Kelly K, Gandara DR, Mack PC. EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLC. Clinical Lung Cancer 2022, 23: 60-71. PMID: 34753703, PMCID: PMC8766941, DOI: 10.1016/j.cllc.2021.10.002.

Wu YL, Tsuboi M, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS. A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer. Future Oncology (London, England) 2021, 17: 4827-4835. PMID: 34723634, DOI: 10.2217/fon-2021-0752.

Roth JA, Trivedi MS, Gray SW, Patrick DL, Delaney DM, Watabayashi K, Litwin P, Shah P, Crew KD, Yee M, Redman MW, Unger JM, Papadimitrakopoulou V, Johnson J, Kelly K, Gandara D, Herbst RS, Hershman DL, Ramsey SD. Patient Knowledge and Expectations About Return of Genomic Results in a Biomarker-Driven Master Protocol Trial (SWOG S1400GEN). JCO Oncology Practice 2021, 17: e1821-e1829. PMID: 33797955, DOI: 10.1200/OP.20.00770.

Jassem J, de Marinis F, Giaccone G, Vergnenegre A, Barrios CH, Morise M, Felip E, Oprean C, Kim YC, Andric Z, Mocci S, Enquist I, Komatsubara K, McCleland M, Kuriki H, Villalobos M, Phan S, Spigel DR, Herbst RS. Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1-Selected NSCLC. Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer 2021, 16: 1872-1882. PMID: 34265434, DOI: 10.1016/j.jtho.2021.06.019.

Herbst RS, Garon EB, Kim DW, Cho BC, Gervais R, Perez-Gracia JL, Han JY, Majem M, Forster MD, Monnet I, Novello S, Gubens MA, Boyer M, Su WC, Samkari A, Jensen EH, Kobie J, Piperdi B, Baas P. Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC. Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer 2021, 16: 1718-1732. PMID: 34048946, DOI: 10.1016/j.jtho.2021.05.001.

Grant MJ, Herbst RS, Goldberg SB. Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC. Nature Reviews. Clinical Oncology 2021, 18: 625-644. PMID: 34168333, DOI: 10.1038/s41571-021-00520-1.

Gettinger SN, Redman MW, Bazhenova L, Hirsch FR, Mack PC, Schwartz LH, Bradley JD, Stinchcombe TE, Leighl NB, Ramalingam SS, Tavernier SS, Yu H, Unger JM, Minichiello K, Highleyman L, Papadimitrakopoulou VA, Kelly K, Gandara DR, Herbst RS. Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial. JAMA Oncology 2021, 7: 1368-1377. PMID: 34264316, PMCID: PMC8283667, DOI: 10.1001/jamaoncol.2021.2209.

Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nature Medicine 2021, 27: 1345-1356. PMID: 34385702, DOI: 10.1038/s41591-021-01450-2.

Leighl NB, Redman MW, Rizvi N, Hirsch FR, Mack PC, Schwartz LH, Wade JL, Irvin WJ, Reddy SC, Crawford J, Bradley JD, Stinchcombe TE, Ramalingam SS, Miao J, Minichiello K, Herbst RS, Papadimitrakopoulou VA, Kelly K, Gandara DR. Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760). Journal For Immunotherapy Of Cancer 2021, 9 PMID: 34429332, PMCID: PMC8386207, DOI: 10.1136/jitc-2021-002973.

Mansfield AS, Herbst RS, de Castro G, Hui R, Peled N, Kim DW, Novello S, Satouchi M, Wu YL, Garon EB, Reck M, Robinson AG, Samkari A, Piperdi B, Ebiana V, Lin J, Mok TSK. Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1-Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042. JTO Clinical And Research Reports 2021, 2: 100205. PMID: 34590048, PMCID: PMC8474394, DOI: 10.1016/j.jtocrr.2021.100205.

Sanmamed MF, Nie X, Desai SS, Villaroel-Espindola F, Badri T, Zhao D, Kim AW, Ji L, Zhang T, Quinlan E, Cheng X, Han X, Vesely MD, Nassar AF, Sun J, Zhang Y, Kim TK, Wang J, Melero I, Herbst RS, Schalper KA, Chen L. A Burned-Out CD8+ T-cell Subset Expands in the Tumor Microenvironment and Curbs Cancer Immunotherapy. Cancer Discovery 2021, 11: 1700-1715. PMID: 33658301, PMCID: PMC9421941, DOI: 10.1158/2159-8290.CD-20-0962.

Jones DR, Wu YL, Tsuboi M, Herbst RS. Targeted therapies for resectable lung adenocarcinoma: ADAURA opens for thoracic oncologic surgeons. The Journal Of Thoracic And Cardiovascular Surgery 2021, 162: 288-292. PMID: 33691940, PMCID: PMC8519337, DOI: 10.1016/j.jtcvs.2021.02.008.

Waqar SN, Redman MW, Arnold SM, Hirsch FR, Mack PC, Schwartz LH, Gandara DR, Stinchcombe TE, Leighl NB, Ramalingam SS, Tanna SH, Raddin RS, Minichiello K, Bradley JD, Kelly K, Herbst RS, Papadimitrakopoulou VA. A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753). Clinical Lung Cancer 2021, 22: 170-177. PMID: 33221175, PMCID: PMC8044254, DOI: 10.1016/j.cllc.2020.09.013.

Borghaei H, Redman MW, Kelly K, Waqar SN, Robert F, Kiefer GJ, Stella PJ, Minichiello K, Gandara DR, Herbst RS, Papadimitrakopoulou VA. SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study). Clinical Lung Cancer 2021, 22: 178-186. PMID: 33358401, PMCID: PMC8686189, DOI: 10.1016/j.cllc.2020.10.015.

Owonikoko TK, Redman MW, Byers LA, Hirsch FR, Mack PC, Schwartz LH, Bradley JD, Stinchcombe TE, Leighl NB, Al Baghdadi T, Lara P, Miao J, Kelly K, Ramalingam SS, Herbst RS, Papadimitrakopoulou V, Gandara DR. Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G. Clinical Lung Cancer 2021, 22: 187-194.e1. PMID: 33583720, PMCID: PMC8637652, DOI: 10.1016/j.cllc.2021.01.001.

Herbst RS, Wu YL, Tsuboi M. Osimertinib in EGFR-Mutated Lung Cancer. Reply. The New England Journal Of Medicine 2021, 384: 675-676. PMID: 33596365, DOI: 10.1056/NEJMc2033951.

Herbst RS, Kuriki H, Spigel DR. Atezolizumab for PD-L1-Selected Patients with NSCLC. Reply. The New England Journal Of Medicine 2021, 384: 584-585. PMID: 33567202, DOI: 10.1056/NEJMc2032432.

Herbst RS, Arkenau HT, Bendell J, Arrowsmith E, Wermke M, Soriano A, Penel N, Santana-Davila R, Bischoff H, Chau I, Mi G, Wang H, Rasmussen E, Ferry D, Chao BH, Paz-Ares L. Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC. Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer 2021, 16: 289-298. PMID: 33068794, DOI: 10.1016/j.jtho.2020.10.004.

Tam AL, Papadimitrakopoulou V, Wistuba II, Lee JJ, Ensor JE, Kim ES, Kalhor N, Blumenschein GR, Tsao AS, Heymach JV, Herbst RS, Hicks ME, Hong WK, Gupta S. The value of interventional radiology in clinical trial teams: experience from the BATTLE lung cancer trials. Clinical Radiology 2021, 76: 155.e25-155.e34. PMID: 33268083, DOI: 10.1016/j.crad.2020.09.024.

Fucito LM, Malinosky H, Baldassarri SR, Herbst RS. Clearing the Haze: What Do We Still Need to Learn about Electronic Nicotine Delivery Systems? Cancer Prevention Research (Philadelphia, Pa.) 2021, 14: 5-10. PMID: 33148678, PMCID: PMC8324047, DOI: 10.1158/1940-6207.CAPR-20-0394.

McPadden J, Warner F, Young HP, Hurley NC, Pulk RA, Singh A, Durant TJS, Gong G, Desai N, Haimovich A, Taylor RA, Gunel M, Dela Cruz CS, Farhadian SF, Siner J, Villanueva M, Churchwell K, Hsiao A, Torre CJ, Velazquez EJ, Herbst RS, Iwasaki A, Ko AI, Mortazavi BJ, Krumholz HM, Schulz WL. Clinical characteristics and outcomes for 7,995 patients with SARS-CoV-2 infection. PloS One 2021, 16: e0243291. PMID: 33788846, PMCID: PMC8011821, DOI: 10.1371/journal.pone.0243291.

Jacobsen PB, Baskin ML, Chen MS, Herbst RS, Lathan CS. How a Priority of Community Outreach and Engagement Is Changing Health Equity at Cancer Centers. Health Equity 2021, 5: 227-235. PMID: 33937609, PMCID: PMC8086529, DOI: 10.1089/heq.2021.29005.rtd.

Herbst R, Jassem J, Abogunrin S, James D, McCool R, Belleli R, Giaccone G, De Marinis F. A Network Meta-Analysis of Cancer Immunotherapies Versus Chemotherapy for First-Line Treatment of Patients With Non-Small Cell Lung Cancer and High Programmed Death-Ligand 1 Expression. Frontiers In Oncology 2021, 11: 676732. PMID: 34307144, PMCID: PMC8300186, DOI: 10.3389/fonc.2021.676732.

Goldberg SB, Redman MW, Lilenbaum R, Politi K, Stinchcombe TE, Horn L, Chen EH, Mashru SH, Gettinger SN, Melnick MA, Herbst RS, Baumgart MA, Miao J, Moon J, Kelly K, Gandara DR. Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR-Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2020, 38: 4076-4085. PMID: 33021871, PMCID: PMC7768342, DOI: 10.1200/JCO.20.01149.

Redman MW, Papadimitrakopoulou VA, Minichiello K, Hirsch FR, Mack PC, Schwartz LH, Vokes E, Ramalingam S, Leighl N, Bradley J, Miao J, Moon J, Highleyman L, Miwa C, LeBlanc ML, Malik S, Miller VA, Sigal EV, Adam S, Wholley D, Sigman C, Smolich B, Blanke CD, Kelly K, Gandara DR, Herbst RS. Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol. The Lancet. Oncology 2020, 21: 1589-1601. PMID: 33125909, PMCID: PMC8109255, DOI: 10.1016/S1470-2045(20)30475-7.

McPadden J, Warner F, Young HP, Hurley NC, Pulk RA, Singh A, Durant TJ, Gong G, Desai N, Haimovich A, Taylor RA, Gunel M, Dela Cruz CS, Farhadian SF, Siner J, Villanueva M, Churchwell K, Hsiao A, Torre CJ, Velazquez EJ, Herbst RS, Iwasaki A, Ko AI, Mortazavi BJ, Krumholz HM, Schulz WL. Clinical Characteristics and Outcomes for 7,995 Patients with SARS-CoV-2 Infection. MedRxiv : The Preprint Server For Health Sciences 2020 PMID: 32743602, PMCID: PMC7386526, DOI: 10.1101/2020.07.19.20157305.

Goldberg SB, Herbst RS. Introduction by the Guest Editors. Cancer Journal (Sudbury, Mass.) 2020, 26: 471-472. PMID: 33298717, DOI: 10.1097/PPO.0000000000000487.

Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. The New England Journal Of Medicine 2020, 383: 1711-1723. PMID: 32955177, DOI: 10.1056/NEJMoa2027071.

Chau I, Penel N, Soriano AO, Arkenau HT, Cultrera J, Santana-Davila R, Calvo E, Le Tourneau C, Zender L, Bendell JC, Mi G, Gao L, McNeely SC, Oliveira JM, Ferry D, Herbst RS, Fuchs CS. Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial. Cancers 2020, 12 PMID: 33076423, PMCID: PMC7602637, DOI: 10.3390/cancers12102985.

Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, Morise M, Felip E, Andric Z, Geater S, Özgüroğlu M, Zou W, Sandler A, Enquist I, Komatsubara K, Deng Y, Kuriki H, Wen X, McCleland M, Mocci S, Jassem J, Spigel DR. Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. The New England Journal Of Medicine 2020, 383: 1328-1339. PMID: 32997907, DOI: 10.1056/NEJMoa1917346.

Zugazagoitia J, Gupta S, Liu Y, Fuhrman K, Gettinger S, Herbst RS, Schalper KA, Rimm DL. Biomarkers Associated with Beneficial PD-1 Checkpoint Blockade in Non-Small Cell Lung Cancer (NSCLC) Identified Using High-Plex Digital Spatial Profiling. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2020, 26: 4360-4368. PMID: 32253229, PMCID: PMC7442721, DOI: 10.1158/1078-0432.CCR-20-0175.

Eguren-Santamaria I, Sanmamed MF, Goldberg SB, Kluger HM, Idoate MA, Lu BY, Corral J, Schalper KA, Herbst RS, Gil-Bazo I. PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical Practice. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2020, 26: 4186-4197. PMID: 32354698, DOI: 10.1158/1078-0432.CCR-20-0798.

Lucas C, Wong P, Klein J, Castro TBR, Silva J, Sundaram M, Ellingson MK, Mao T, Oh JE, Israelow B, Takahashi T, Tokuyama M, Lu P, Venkataraman A, Park A, Mohanty S, Wang H, Wyllie AL, Vogels CBF, Earnest R, Lapidus S, Ott IM, Moore AJ, Muenker MC, Fournier JB, Campbell M, Odio CD, Casanovas-Massana A, Herbst R, Shaw AC, Medzhitov R, Schulz WL, Grubaugh ND, Dela Cruz C, Farhadian S, Ko AI, Omer SB, Iwasaki A. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature 2020, 584: 463-469. PMID: 32717743, PMCID: PMC7477538, DOI: 10.1038/s41586-020-2588-y.

Remon J, Passiglia F, Ahn MJ, Barlesi F, Forde PM, Garon EB, Gettinger S, Goldberg SB, Herbst RS, Horn L, Kubota K, Lu S, Mezquita L, Paz-Ares L, Popat S, Schalper KA, Skoulidis F, Reck M, Adjei AA, Scagliotti GV. Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer 2020, 15: 914-947. PMID: 32179179, DOI: 10.1016/j.jtho.2020.03.006.

Herbst RS, Garon EB, Kim DW, Cho BC, Perez-Gracia JL, Han JY, Arvis CD, Majem M, Forster MD, Monnet I, Novello S, Szalai Z, Gubens MA, Su WC, Ceresoli GL, Samkari A, Jensen EH, Lubiniecki GM, Baas P. Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2020, 38: 1580-1590. PMID: 32078391, DOI: 10.1200/JCO.19.02446.

Goldberg SB, Schalper KA, Gettinger SN, Mahajan A, Herbst RS, Chiang AC, Lilenbaum R, Wilson FH, Omay SB, Yu JB, Jilaveanu L, Tran T, Pavlik K, Rowen E, Gerrish H, Komlo A, Gupta R, Wyatt H, Ribeiro M, Kluger Y, Zhou G, Wei W, Chiang VL, Kluger HM. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. The Lancet. Oncology 2020, 21: 655-663. PMID: 32251621, PMCID: PMC7380514, DOI: 10.1016/S1470-2045(20)30111-X.

Liu Y, Zugazagoitia J, Ahmed FS, Henick BS, Gettinger S, Herbst RS, Schalper KA, Rimm DL. Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2020, 26: 970-977. PMID: 31615933, PMCID: PMC7024671, DOI: 10.1158/1078-0432.CCR-19-1040.

Chiang AC, Herbst RS. Frontline immunotherapy for NSCLC - the tale of the tail. Nature Reviews. Clinical Oncology 2020, 17: 73-74. PMID: 31907372, DOI: 10.1038/s41571-019-0317-y.

Reuben A, Zhang J, Chiou SH, Gittelman RM, Li J, Lee WC, Fujimoto J, Behrens C, Liu X, Wang F, Quek K, Wang C, Kheradmand F, Chen R, Chow CW, Lin H, Bernatchez C, Jalali A, Hu X, Wu CJ, Eterovic AK, Parra ER, Yusko E, Emerson R, Benzeno S, Vignali M, Wu X, Ye Y, Little LD, Gumbs C, Mao X, Song X, Tippen S, Thornton RL, Cascone T, Snyder A, Wargo JA, Herbst R, Swisher S, Kadara H, Moran C, Kalhor N, Zhang J, Scheet P, Vaporciyan AA, Sepesi B, Gibbons DL, Robins H, Hwu P, Heymach JV, Sharma P, Allison JP, Baladandayuthapani V, Lee JJ, Davis MM, Wistuba II, Futreal PA, Zhang J. Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nature Communications 2020, 11: 603. PMID: 32001676, PMCID: PMC6992630, DOI: 10.1038/s41467-019-14273-0.

Herbst RS, Aisner DL, Sonett JR, Turk AT, Weintraub JL, Lindeman NI. Practical Considerations Relating to Routine Clinical Biomarker Testing for Non-small Cell Lung Cancer: Focus on Testing for RET Fusions. Frontiers In Medicine 2020, 7: 562480. PMID: 33553195, PMCID: PMC7859651, DOI: 10.3389/fmed.2020.562480.

Zugazagoitia J, Liu Y, Toki M, McGuire J, Ahmed FS, Henick BS, Gupta R, Gettinger S, Herbst R, Schalper KA, Rimm DL. Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non-Small Cell Lung Cancer. Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer 2019, 14: 2084-2096. PMID: 31605795, PMCID: PMC6951804, DOI: 10.1016/j.jtho.2019.09.014.

Herbst RS, Schlessinger J. Small molecule combats cancer-causing KRAS protein at last. Nature 2019, 575: 294-295. PMID: 31705127, DOI: 10.1038/d41586-019-03242-8.

Langer CJ, Redman MW, Wade JL, Aggarwal C, Bradley JD, Crawford J, Stella PJ, Knapp MH, Miao J, Minichiello K, Herbst RS, Kelly K, Gandara DR, Papadimitrakopoulou VA. SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study). Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer 2019, 14: 1839-1846. PMID: 31158500, PMCID: PMC7017958, DOI: 10.1016/j.jtho.2019.05.029.

Aggarwal C, Redman MW, Lara PN, Borghaei H, Hoffman P, Bradley JD, Newman AJ, Feldman MJ, Minichiello K, Miao J, Mack PC, Papadimitrakopoulou VA, Herbst RS, Kelly K, Gandara DR. SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy). Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer 2019, 14: 1847-1852. PMID: 31195180, PMCID: PMC6901020, DOI: 10.1016/j.jtho.2019.05.041.

Edelman MJ, Redman MW, Albain KS, McGary EC, Rafique NM, Petro D, Waqar SN, Minichiello K, Miao J, Papadimitrakopoulou VA, Kelly K, Gandara DR, Herbst RS. SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy). Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer 2019, 14: 1853-1859. PMID: 31302234, PMCID: PMC6764876, DOI: 10.1016/j.jtho.2019.06.027.

Dong MB, Wang G, Chow RD, Ye L, Zhu L, Dai X, Park JJ, Kim HR, Errami Y, Guzman CD, Zhou X, Chen KY, Renauer PA, Du Y, Shen J, Lam SZ, Zhou JJ, Lannin DR, Herbst RS, Chen S. Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells. Cell 2019, 178: 1189-1204.e23. PMID: 31442407, PMCID: PMC6719679, DOI: 10.1016/j.cell.2019.07.044.

Doroshow DB, Sanmamed MF, Hastings K, Politi K, Rimm DL, Chen L, Melero I, Schalper KA, Herbst RS. Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2019, 25: 4592-4602. PMID: 30824587, PMCID: PMC6679805, DOI: 10.1158/1078-0432.CCR-18-1538.

Hastings K, Yu HA, Wei W, Sanchez-Vega F, DeVeaux M, Choi J, Rizvi H, Lisberg A, Truini A, Lydon CA, Liu Z, Henick BS, Wurtz A, Cai G, Plodkowski AJ, Long NM, Halpenny DF, Killam J, Oliva I, Schultz N, Riely GJ, Arcila ME, Ladanyi M, Zelterman D, Herbst RS, Goldberg SB, Awad MM, Garon EB, Gettinger S, Hellmann MD, Politi K. EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2019, 30: 1311-1320. PMID: 31086949, PMCID: PMC6683857, DOI: 10.1093/annonc/mdz141.

Datar IJ, Sanmamed MF, Wang J, Henick BS, Choi J, Badri T, Dong W, Mani N, Toki MI, Mejías L, Lozano MD, Perez-Gracia JL, Velcheti V, Hellmann MD, Gainor JF, McEachern K, Jenkins D, Syrigos KN, Politi K, Gettinger S, Rimm DL, Herbst RS, Melero I, Chen L, Schalper KA. Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2019, 25: 4663-4673. PMID: 31053602, PMCID: PMC7444693, DOI: 10.1158/1078-0432.CCR-18-4142.

Herbst RS, Arkenau HT, Santana-Davila R, Calvo E, Paz-Ares L, Cassier PA, Bendell J, Penel N, Krebs MG, Martin-Liberal J, Isambert N, Soriano A, Wermke M, Cultrera J, Gao L, Widau RC, Mi G, Jin J, Ferry D, Fuchs CS, Petrylak DP, Chau I. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. The Lancet. Oncology 2019, 20: 1109-1123. PMID: 31301962, DOI: 10.1016/S1470-2045(19)30458-9.

Burd A, Schilsky RL, Byrd JC, Levine RL, Papadimitrakopoulou VA, Herbst RS, Redman MW, Druker BJ, Gandara DR. Challenges and approaches to implementing master/basket trials in oncology. Blood Advances 2019, 3: 2237-2243. PMID: 31337605, PMCID: PMC6650731, DOI: 10.1182/bloodadvances.2019031229.

Riaz F, Presley CJ, Chiang AC, Longtine JA, Soulos PR, Adelson KB, Herbst RS, Nussbaum NC, Sorg RA, Abernethy AP, Agarwala V, Gross CP. Disparities in broad-based genomic sequencing for patients with advanced non-small cell lung cancer. Journal Of Geriatric Oncology 2019, 10: 669-672. PMID: 30718180, DOI: 10.1016/j.jgo.2019.01.016.

Lee JW, Zhang Y, Eoh KJ, Sharma R, Sanmamed MF, Wu J, Choi J, Park HS, Iwasaki A, Kaftan E, Chen L, Papadimitrakopoulou V, Herbst RS, Koo JS. The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer. Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer 2019, 14: 1046-1060. PMID: 30771521, PMCID: PMC6542636, DOI: 10.1016/j.jtho.2019.02.004.

Altan M, Toki MI, Gettinger SN, Carvajal-Hausdorf DE, Zugazagoitia J, Sinard JH, Herbst RS, Rimm DL. Immune Checkpoint Inhibitor-Associated Pericarditis. Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer 2019, 14: 1102-1108. PMID: 30851443, PMCID: PMC6617516, DOI: 10.1016/j.jtho.2019.02.026.

Khuri FR, Herbst RS. The fork in the road: Waun Ki Hong, John Mendelsohn, and the reinvigoration of The University of Texas MD Anderson Cancer Center. Cancer 2019, 125: 1593-1596. PMID: 30825386, DOI: 10.1002/cncr.32045.

Barlesi F, Garon EB, Kim DW, Felip E, Han JY, Kim JH, Ahn MJ, Fidler MJ, Gubens MA, de Castro G, Surmont V, Li Q, Deitz AC, Lubiniecki GM, Herbst RS. Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC. Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer 2019, 14: 793-801. PMID: 30711649, DOI: 10.1016/j.jtho.2019.01.016.

Wang J, Sun J, Liu LN, Flies DB, Nie X, Toki M, Zhang J, Song C, Zarr M, Zhou X, Han X, Archer KA, O'Neill T, Herbst RS, Boto AN, Sanmamed MF, Langermann S, Rimm DL, Chen L. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. Nature Medicine 2019, 25: 656-666. PMID: 30833750, PMCID: PMC7175920, DOI: 10.1038/s41591-019-0374-x.

Wilson FH, Herbst RS. Larotrectinib in NTRK-Rearranged Solid TumorsPublished as part of the Biochemistry series "Biochemistry to Bedside". Biochemistry 2019, 58: 1555-1557. PMID: 30865435, PMCID: PMC7356829, DOI: 10.1021/acs.biochem.9b00126.

Carvajal-Hausdorf D, Altan M, Velcheti V, Gettinger SN, Herbst RS, Rimm DL, Schalper KA. Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC). Journal For Immunotherapy Of Cancer 2019, 7: 65. PMID: 30850021, PMCID: PMC6408760, DOI: 10.1186/s40425-019-0540-1.

Peled M, Onn A, Herbst RS. Tumor-Infiltrating Lymphocytes-Location for Prognostic Evaluation. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2019, 25: 1449-1451. PMID: 30567833, DOI: 10.1158/1078-0432.CCR-18-3803.

Codina A, Renauer PA, Wang G, Chow RD, Park JJ, Ye H, Zhang K, Dong MB, Gassaway B, Ye L, Errami Y, Shen L, Chang A, Jain D, Herbst RS, Bosenberg M, Rinehart J, Fan R, Chen S. Convergent Identification and Interrogation of Tumor-Intrinsic Factors that Modulate Cancer Immunity In Vivo. Cell Systems 2019, 8: 136-151.e7. PMID: 30797773, PMCID: PMC6592847, DOI: 10.1016/j.cels.2019.01.004.

Herbst RS, Baas P, Perez-Gracia JL, Felip E, Kim DW, Han JY, Molina JR, Kim JH, Dubos Arvis C, Ahn MJ, Majem M, Fidler MJ, Surmont V, de Castro G, Garrido M, Shentu Y, Emancipator K, Samkari A, Jensen EH, Lubiniecki GM, Garon EB. Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2019, 30: 281-289. PMID: 30657853, PMCID: PMC6931268, DOI: 10.1093/annonc/mdy545.

Herbst RS, Baas P, Perez-Gracia JL, Felip E, Kim DW, Han JY, Molina JR, Kim JH, Dubos Arvis C, Ahn MJ, Majem M, Fidler MJ, Surmont V, de Castro G, Garrido M, Shentu Y, Emancipator K, Samkari A, Jensen EH, Lubiniecki GM, Garon EB. Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2019, 30: 281-289. PMID: 31987426, DOI: 10.1093/annonc/mdy545.

Goldberg SB, Herbst RS. Should chemotherapy plus immune checkpoint inhibition be the standard front-line therapy for patients with metastatic non-small cell lung cancer? Cancer 2018, 124: 4592-4596. PMID: 30383887, PMCID: PMC6443243, DOI: 10.1002/cncr.31681.

Arkenau HT, Martin-Liberal J, Calvo E, Penel N, Krebs MG, Herbst RS, Walgren RA, Widau RC, Mi G, Jin J, Ferry D, Chau I. Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF). The Oncologist 2018, 23: 1407-e136. PMID: 29853658, PMCID: PMC6292555, DOI: 10.1634/theoncologist.2018-0044.

Herbst RS, Garon EB, Kim DW, Chul Cho B, Pérez Gracia JL, Han JY, Dubos Arvis C, Majem M, Forster M, Monnet I, Novello S, Szalai Z, Gubens MA, Su WC, Ceresoli GL, Samkari A, Jensen E, Lubiniecki GM, Baas P. Long-term survival in patients (pts) with advanced NSCLC in the KEYNOTE-010 study overall and in pts who completed two years of pembrolizumab (pembro). Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2018, 29 Suppl 8: viii749. PMID: 32138044, DOI: 10.1093/annonc/mdy424.075.

Ruder D, Papadimitrakopoulou V, Shien K, Behrens C, Kalhor N, Chen H, Shen L, Lee JJ, Hong WK, Tang X, Girard L, Minna JD, Diao L, Wang J, Mino B, Villalobos P, Rodriguez-Canales J, Hanson NE, Sun J, Miller V, Greenbowe J, Frampton G, Herbst RS, Baladandayuthapani V, Wistuba II, Izzo JG. Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of RICTOR/KRAS-altered non-small cell lung cancer. Oncotarget 2018, 9: 33995-34008. PMID: 30338041, PMCID: PMC6188056, DOI: 10.18632/oncotarget.26129.

Rolfo C, Mack PC, Scagliotti GV, Baas P, Barlesi F, Bivona TG, Herbst RS, Mok TS, Peled N, Pirker R, Raez LE, Reck M, Riess JW, Sequist LV, Shepherd FA, Sholl LM, Tan DS, Wakelee HA, Wistuba II, Wynes MW, Carbone DP, Hirsch FR, Gandara DR. Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC. Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer 2018, 13: 1248-1268. PMID: 29885479, DOI: 10.1016/j.jtho.2018.05.030.

Horn L, Gettinger SN, Gordon MS, Herbst RS, Gandhi L, Felip E, Sequist LV, Spigel DR, Antonia SJ, Balmanoukian A, Cassier PA, Liu B, Kowanetz M, O'Hear C, Fassò M, Grossman W, Sandler A, Soria JC. Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. European Journal Of Cancer (Oxford, England : 1990) 2018, 101: 201-209. PMID: 30077125, DOI: 10.1016/j.ejca.2018.06.031.

Gettinger SN, Choi J, Mani N, Sanmamed MF, Datar I, Sowell R, Du VY, Kaftan E, Goldberg S, Dong W, Zelterman D, Politi K, Kavathas P, Kaech S, Yu X, Zhao H, Schlessinger J, Lifton R, Rimm DL, Chen L, Herbst RS, Schalper KA. A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers. Nature Communications 2018, 9: 3196. PMID: 30097571, PMCID: PMC6086912, DOI: 10.1038/s41467-018-05032-8.

Presley CJ, Tang D, Soulos PR, Chiang AC, Longtine JA, Adelson KB, Herbst RS, Zhu W, Nussbaum NC, Sorg RA, Agarwala V, Abernethy AP, Gross CP. Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non-Small Cell Lung Cancer in the Community Oncology Setting. JAMA 2018, 320: 469-477. PMID: 30088010, PMCID: PMC6142984, DOI: 10.1001/jama.2018.9824.

Kim TK, Herbst RS, Chen L. Defining and Understanding Adaptive Resistance in Cancer Immunotherapy. Trends In Immunology 2018, 39: 624-631. PMID: 29802087, PMCID: PMC6066429, DOI: 10.1016/j.it.2018.05.001.

Brahmer JR, Govindan R, Anders RA, Antonia SJ, Sagorsky S, Davies MJ, Dubinett SM, Ferris A, Gandhi L, Garon EB, Hellmann MD, Hirsch FR, Malik S, Neal JW, Papadimitrakopoulou VA, Rimm DL, Schwartz LH, Sepesi B, Yeap BY, Rizvi NA, Herbst RS. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). Journal For Immunotherapy Of Cancer 2018, 6: 75. PMID: 30012210, PMCID: PMC6048854, DOI: 10.1186/s40425-018-0382-2.

Wu YL, Herbst RS, Mann H, Rukazenkov Y, Marotti M, Tsuboi M. ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection. Clinical Lung Cancer 2018, 19: e533-e536. PMID: 29789220, DOI: 10.1016/j.cllc.2018.04.004.

Gettinger SN, Wurtz A, Goldberg SB, Rimm D, Schalper K, Kaech S, Kavathas P, Chiang A, Lilenbaum R, Zelterman D, Politi K, Herbst R. Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non-Small Cell Lung Cancer. Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer 2018, 13: 831-839. PMID: 29578107, PMCID: PMC6485248, DOI: 10.1016/j.jtho.2018.03.008.

Goldberg SB, Narayan A, Kole AJ, Decker RH, Teysir J, Carriero NJ, Lee A, Nemati R, Nath SK, Mane SM, Deng Y, Sukumar N, Zelterman D, Boffa DJ, Politi K, Gettinger S, Wilson LD, Herbst RS, Patel AA. Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2018, 24: 1872-1880. PMID: 29330207, PMCID: PMC5899677, DOI: 10.1158/1078-0432.CCR-17-1341.

Doroshow DB, Herbst RS. Treatment of Advanced Non-Small Cell Lung Cancer in 2018. JAMA Oncology 2018, 4: 569-570. PMID: 29494728, DOI: 10.1001/jamaoncol.2017.5190.

Villarroel-Espindola F, Yu X, Datar I, Mani N, Sanmamed MF, Velcheti V, Syrigos KN, Toki MI, Zhao H, Chen L, Herbst RS, Schalper KA. Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2018, 24: 1562-1573. PMID: 29203588, PMCID: PMC5884702, DOI: 10.1158/1078-0432.CCR-17-2542.

Kadara H, Choi M, Zhang J, Parra ER, Rodriguez-Canales J, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Yoo Y, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach J, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee J, Lifton RP, Wistuba II, Herbst RS. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2018, 29: 1072. PMID: 29688333, PMCID: PMC6887935, DOI: 10.1093/annonc/mdx062.

Lee CK, Man J, Lord S, Cooper W, Links M, Gebski V, Herbst RS, Gralla RJ, Mok T, Yang JC. Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis. JAMA Oncology 2018, 4: 210-216. PMID: 29270615, PMCID: PMC5838598, DOI: 10.1001/jamaoncol.2017.4427.

Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature 2018, 553: 446-454. PMID: 29364287, DOI: 10.1038/nature25183.

Herbst RS, Redman MW, Kim ES, Semrad TJ, Bazhenova L, Masters G, Oettel K, Guaglianone P, Reynolds C, Karnad A, Arnold SM, Varella-Garcia M, Moon J, Mack PC, Blanke CD, Hirsch FR, Kelly K, Gandara DR. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. The Lancet. Oncology 2018, 19: 101-114. PMID: 29169877, PMCID: PMC5847342, DOI: 10.1016/S1470-2045(17)30694-0.

Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R, Wurtz A, Dong W, Cai G, Melnick MA, Du VY, Schlessinger J, Goldberg SB, Chiang A, Sanmamed MF, Melero I, Agorreta J, Montuenga LM, Lifton R, Ferrone S, Kavathas P, Rimm DL, Kaech SM, Schalper K, Herbst RS, Politi K. Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. Cancer Discovery 2017, 7: 1420-1435. PMID: 29025772, PMCID: PMC5718941, DOI: 10.1158/2159-8290.CD-17-0593.

Korde A, Jin L, Zhang JG, Ramaswamy A, Hu B, Kolahian S, Guardela BJ, Herazo-Maya J, Siegfried JM, Stabile L, Pisani MA, Herbst RS, Kaminski N, Elias JA, Puchalski JT, Takyar SS. Lung Endothelial MicroRNA-1 Regulates Tumor Growth and Angiogenesis. American Journal Of Respiratory And Critical Care Medicine 2017, 196: 1443-1455. PMID: 28853613, PMCID: PMC5736970, DOI: 10.1164/rccm.201610-2157OC.

Nilsson MB, Sun H, Diao L, Tong P, Liu D, Li L, Fan Y, Poteete A, Lim SO, Howells K, Haddad V, Gomez D, Tran H, Pena GA, Sequist LV, Yang JC, Wang J, Kim ES, Herbst R, Lee JJ, Hong WK, Wistuba I, Hung MC, Sood AK, Heymach JV. Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers. Science Translational Medicine 2017, 9 PMID: 29118262, PMCID: PMC5870120, DOI: 10.1126/scitranslmed.aao4307.

Slovak R, Ludwig JM, Gettinger SN, Herbst RS, Kim HS. Immuno-thermal ablations - boosting the anticancer immune response. Journal For Immunotherapy Of Cancer 2017, 5: 78. PMID: 29037259, PMCID: PMC5644150, DOI: 10.1186/s40425-017-0284-8.

Shien K, Papadimitrakopoulou VA, Ruder D, Behrens C, Shen L, Kalhor N, Song J, Lee JJ, Wang J, Tang X, Herbst RS, Toyooka S, Girard L, Minna JD, Kurie JM, Wistuba II, Izzo JG. JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non-Small Cell Lung Cancer. Molecular Cancer Therapeutics 2017, 16: 2234-2245. PMID: 28729401, PMCID: PMC5628136, DOI: 10.1158/1535-7163.MCT-17-0148.

Cascone T, Xu L, Lin HY, Liu W, Tran HT, Liu Y, Howells K, Haddad V, Hanrahan E, Nilsson MB, Cortez MA, Giri U, Kadara H, Saigal B, Park YY, Peng W, Lee JS, Ryan AJ, Jüergensmeier JM, Herbst RS, Wang J, Langley RR, Wistuba II, Lee JJ, Heymach JV. The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2017, 23: 5489-5501. PMID: 28559461, PMCID: PMC5600821, DOI: 10.1158/1078-0432.CCR-16-3216.

Altan M, Pelekanou V, Schalper KA, Toki M, Gaule P, Syrigos K, Herbst RS, Rimm DL. B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2017, 23: 5202-5209. PMID: 28539467, PMCID: PMC5581684, DOI: 10.1158/1078-0432.CCR-16-3107.

Newman JH, Rich S, Abman SH, Alexander JH, Barnard J, Beck GJ, Benza RL, Bull TM, Chan SY, Chun HJ, Doogan D, Dupuis J, Erzurum SC, Frantz RP, Geraci M, Gillies H, Gladwin M, Gray MP, Hemnes AR, Herbst RS, Hernandez AF, Hill NS, Horn EM, Hunter K, Jing ZC, Johns R, Kaul S, Kawut SM, Lahm T, Leopold JA, Lewis GD, Mathai SC, McLaughlin VV, Michelakis ED, Nathan SD, Nichols W, Page G, Rabinovitch M, Rich J, Rischard F, Rounds S, Shah SJ, Tapson VF, Lowy N, Stockbridge N, Weinmann G, Xiao L. Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI-Cardiovascular Medical Research and Education Fund Workshop Report. American Journal Of Respiratory And Critical Care Medicine 2017, 195: 1661-1670. PMID: 28430547, PMCID: PMC5476915, DOI: 10.1164/rccm.201701-0150WS.

Arkenau HT, Bendell J, Herbst R, Mi G, Jin J, Rege J, Ferry D, Chau I. Ramucirumab plus pembrolizumab in previously treated advanced or metastatic biliary tract cancer: A multi-disease phase 1 study. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2017, 28 Suppl 3: iii144-iii145. PMID: 32135778, DOI: 10.1093/annonc/mdx262.018.

Salazar MC, Rosen JE, Wang Z, Arnold BN, Thomas DC, Herbst RS, Kim AW, Detterbeck FC, Blasberg JD, Boffa DJ. Association of Delayed Adjuvant Chemotherapy With Survival After Lung Cancer Surgery. JAMA Oncology 2017, 3: 610-619. PMID: 28056112, PMCID: PMC5824207, DOI: 10.1001/jamaoncol.2016.5829.

Stevens LE, Cheung WKC, Adua SJ, Arnal-Estapé A, Zhao M, Liu Z, Brewer K, Herbst RS, Nguyen DX. Extracellular Matrix Receptor Expression in Subtypes of Lung Adenocarcinoma Potentiates Outgrowth of Micrometastases. Cancer Research 2017, 77: 1905-1917. PMID: 28196904, PMCID: PMC5468792, DOI: 10.1158/0008-5472.CAN-16-1978.

Zhong H, Fazenbaker C, Chen C, Breen S, Huang J, Yao X, Ren P, Yao Y, Herbst R, Hollingsworth RE. Overproduction of IGF-2 drives a subset of colorectal cancer cells, which specifically respond to an anti-IGF therapeutic antibody and combination therapies. Oncogene 2017, 36: 797-806. PMID: 27399333, DOI: 10.1038/onc.2016.248.

Du L, Herbst RS, Morgensztern D. Immunotherapy in Lung Cancer. Hematology/oncology Clinics Of North America 2017, 31: 131-141. PMID: 27912829, DOI: 10.1016/j.hoc.2016.08.004.

Morgensztern D, Herbst RS. Evolving Treatment Options for Lung Cancer. Hematology/oncology Clinics Of North America 2017, 31: xiii-xiv. PMID: 27912837, DOI: 10.1016/j.hoc.2016.09.001.

Schalper KA, Carvajal-Hausdorf D, McLaughlin J, Altan M, Velcheti V, Gaule P, Sanmamed MF, Chen L, Herbst RS, Rimm DL. Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2017, 23: 370-378. PMID: 27440266, PMCID: PMC6350535, DOI: 10.1158/1078-0432.CCR-16-0150.

Choi M, Kadara H, Zhang J, Parra ER, Rodriguez-Canales J, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Kim K, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach J, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee J, Lifton RP, Herbst RS, Wistuba II. Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2017, 28: 83-89. PMID: 28177435, PMCID: PMC6246501, DOI: 10.1093/annonc/mdw437.

Kadara H, Choi M, Zhang J, Parra ER, Rodriguez-Canales J, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Yoo Y, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach J, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee J, Lifton RP, Wistuba II, Herbst RS. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2017, 28: 75-82. PMID: 27687306, PMCID: PMC5982809, DOI: 10.1093/annonc/mdw436.

Kadara H, Choi M, Zhang J, Parra ER, Rodriguez-Canales J, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Yoo Y, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach J, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee J, Lifton RP, Wistuba II, Herbst RS. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2017, 28: 75-82. PMID: 31792518, DOI: 10.1093/annonc/mdw436.

Herbst RS, De Marinis F, Jassem J, Lam S, Mocci S, Sandler A, Lopez-Chavez A, Deng Y, Giaccone G, Spigel DR. PS01.56: IMpower110: Phase III Trial Comparing 1L Atezolizumab with Chemotherapy in PD-L1-Selected Chemotherapy-Naive NSCLC Patients: Topic: Medical Oncology. Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer 2016, 11: S304-S305. PMID: 27969523, DOI: 10.1016/j.jtho.2016.09.091.

Shields PG, Herbst RS, Arenberg D, Benowitz NL, Bierut L, Luckart JB, Cinciripini P, Collins B, David S, Davis J, Hitsman B, Hyland A, Lang M, Leischow S, Park ER, Purcell WT, Selzle J, Silber A, Spencer S, Tanvetyanon T, Tiep B, Tindle HA, Tucker-Seeley R, Urbanic J, Hooper MW, Weksler B, Whitlock CW, Wood DE, Burns J, Scavone J. Smoking Cessation, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network : JNCCN 2016, 14: 1430-1468. PMID: 27799513, DOI: 10.6004/jnccn.2016.0152.

Gordon MS, Herbst RS, Horn L, Soria JC, Gandhi L, Felip E, Sequist L, Spigel DR, Antonia SJ, Balmanoukian A, Cassier P, Liu B, Kowanetz M, O'Hear C, Fassò M, Sandler A, Gettinger SN. PS01.62: Long-Term Safety and Clinical Activity of Atezolizumab Monotherapy in Metastatic NSCLC: Final Results from a Phase Ia Study: Topic: Medical Oncology. Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer 2016, 11: S309-S310. PMID: 27969529, DOI: 10.1016/j.jtho.2016.09.097.

Herbst RS, Sznol M. Diminished but not dead: chemotherapy for the treatment of NSCLC. The Lancet. Oncology 2016, 17: 1464-1465. PMID: 27819227, DOI: 10.1016/S1470-2045(16)30524-1.

Papadimitrakopoulou V, Lee JJ, Wistuba II, Tsao AS, Fossella FV, Kalhor N, Gupta S, Byers LA, Izzo JG, Gettinger SN, Goldberg SB, Tang X, Miller VA, Skoulidis F, Gibbons DL, Shen L, Wei C, Diao L, Peng SA, Wang J, Tam AL, Coombes KR, Koo JS, Mauro DJ, Rubin EH, Heymach JV, Hong WK, Herbst RS. The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2016, 34: 3638-3647. PMID: 27480147, PMCID: PMC5065110, DOI: 10.1200/JCO.2015.66.0084.

Herbst RS, Baas P, Perez-Gracia JL, Felip E, Kim DW, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, Surmont V, De Castro G, Garrido M, Shentu Y, Dolled-Filhart M, Im E, Garon EB. P2.41 (also presented as PD1.06): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment: Track: Immunotherapy. Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer 2016, 11: S242-S243. PMID: 27676575, DOI: 10.1016/j.jtho.2016.08.112.

Herbst RS, Baas P, Perez-Gracia JL, Felip E, Kim DW, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, Surmont V, De Castro G, Garrido M, Shentu Y, Dolled-Filhart M, Im E, Garon EB. PD1.06 (also presented as P2.41): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment. Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer 2016, 11: S174-S175. PMID: 27676480, DOI: 10.1016/j.jtho.2016.08.014.

Choi M, Kadara H, Zhang J, Cuentas EP, Canales JR, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Kim K, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach J, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee JJ, Lifton RP, Herbst RS, Wistuba II. Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2016 PMID: 27687303, DOI: 10.1093/annonc/mdw437.

Waqar SN, Bonomi PD, Govindan R, Hirsch FR, Riely GJ, Papadimitrakopoulou V, Kazandjian D, Khozin S, Larkins E, Dickson DJ, Malik S, Horn L, Ferris A, Shaw AT, Jänne PA, Mok TS, Herbst R, Keegan P, Pazdur R, Blumenthal GM. Clinician Perspectives on Current Issues in Lung Cancer Drug Development. Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer 2016, 11: 1387-96. PMID: 27401214, PMCID: PMC5131641, DOI: 10.1016/j.jtho.2016.05.009.

Morgensztern D, Herbst RS. Nivolumab and Pembrolizumab for Non-Small Cell Lung Cancer. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2016, 22: 3713-7. PMID: 27252413, DOI: 10.1158/1078-0432.CCR-15-2998.

Tan DS, Yom SS, Tsao MS, Pass HI, Kelly K, Peled N, Yung RC, Wistuba II, Yatabe Y, Unger M, Mack PC, Wynes MW, Mitsudomi T, Weder W, Yankelevitz D, Herbst RS, Gandara DR, Carbone DP, Bunn PA, Mok TS, Hirsch FR. The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016. Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer 2016, 11: 946-63. PMID: 27229180, DOI: 10.1016/j.jtho.2016.05.008.

Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, Tsiouris AJ, Cohen J, Vortmeyer A, Jilaveanu L, Yu J, Hegde U, Speaker S, Madura M, Ralabate A, Rivera A, Rowen E, Gerrish H, Yao X, Chiang V, Kluger HM. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. The Lancet. Oncology 2016, 17: 976-983. PMID: 27267608, PMCID: PMC5526047, DOI: 10.1016/S1470-2045(16)30053-5.

Gu X, Chen N, Wei C, Liu S, Papadimitrakopoulou VA, Herbst RS, Lee JJ. Bayesian Two-stage Biomarker-based Adaptive Design for Targeted Therapy Development. Statistics In Biosciences 2016, 8: 99-128. PMID: 27617040, PMCID: PMC5014437, DOI: 10.1007/s12561-014-9124-2.

Schalper KA, Kaftan E, Herbst RS. Predictive Biomarkers for PD-1 Axis Therapies: The Hidden Treasure or a Call for Research. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2016, 22: 2102-4. PMID: 26957559, PMCID: PMC4940186, DOI: 10.1158/1078-0432.CCR-16-0169.

Tsao AS, Scagliotti GV, Bunn PA, Carbone DP, Warren GW, Bai C, de Koning HJ, Yousaf-Khan AU, McWilliams A, Tsao MS, Adusumilli PS, Rami-Porta R, Asamura H, Van Schil PE, Darling GE, Ramalingam SS, Gomez DR, Rosenzweig KE, Zimmermann S, Peters S, Ignatius Ou SH, Reungwetwattana T, Jänne PA, Mok TS, Wakelee HA, Pirker R, Mazières J, Brahmer JR, Zhou Y, Herbst RS, Papadimitrakopoulou VA, Redman MW, Wynes MW, Gandara DR, Kelly RJ, Hirsch FR, Pass HI. Scientific Advances in Lung Cancer 2015. Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer 2016, 11: 613-638. PMID: 27013409, DOI: 10.1016/j.jtho.2016.03.012.

Land SR, Toll BA, Moinpour CM, Mitchell SA, Ostroff JS, Hatsukami DK, Duffy SA, Gritz ER, Rigotti NA, Brandon TH, Prindiville SA, Sarna LP, Schnoll RA, Herbst RS, Cinciripini PM, Leischow SJ, Dresler CM, Fiore MC, Warren GW. Research Priorities, Measures, and Recommendations for Assessment of Tobacco Use in Clinical Cancer Research. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2016, 22: 1907-13. PMID: 26888828, PMCID: PMC4861174, DOI: 10.1158/1078-0432.CCR-16-0104.

Nilsson MB, Giri U, Gudikote J, Tang X, Lu W, Tran H, Fan Y, Koo A, Diao L, Tong P, Wang J, Herbst R, Johnson BE, Ryan A, Webster A, Rowe P, Wistuba II, Heymach JV. KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2016, 22: 1940-50. PMID: 26578684, PMCID: PMC4834253, DOI: 10.1158/1078-0432.CCR-15-1994.

Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016, 387: 1540-1550. PMID: 26712084, DOI: 10.1016/S0140-6736(15)01281-7.

Hedberg ML, Goh G, Chiosea SI, Bauman JE, Freilino ML, Zeng Y, Wang L, Diergaarde BB, Gooding WE, Lui VW, Herbst RS, Lifton RP, Grandis JR. Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma. The Journal Of Clinical Investigation 2016, 126: 1606. PMID: 27035818, PMCID: PMC4811141, DOI: 10.1172/JCI86862.

Xia B, Herbst RS. Immune checkpoint therapy for non-small-cell lung cancer: an update. Immunotherapy 2016, 8: 279-98. PMID: 26860624, DOI: 10.2217/imt.15.123.

Hedberg ML, Goh G, Chiosea SI, Bauman JE, Freilino ML, Zeng Y, Wang L, Diergaarde BB, Gooding WE, Lui VW, Herbst RS, Lifton RP, Grandis JR. Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma. The Journal Of Clinical Investigation 2016, 126: 169-80. PMID: 26619122, PMCID: PMC4701554, DOI: 10.1172/JCI82066.

McLaughlin J, Han G, Schalper KA, Carvajal-Hausdorf D, Pelekanou V, Rehman J, Velcheti V, Herbst R, LoRusso P, Rimm DL. Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer. JAMA Oncology 2016, 2: 46-54. PMID: 26562159, PMCID: PMC4941982, DOI: 10.1001/jamaoncol.2015.3638.

Park SA, Lee JW, Herbst RS, Koo JS. GSK-3α Is a Novel Target of CREB and CREB-GSK-3α Signaling Participates in Cell Viability in Lung Cancer. PloS One 2016, 11: e0153075. PMID: 27049759, PMCID: PMC4822949, DOI: 10.1371/journal.pone.0153075.

Park SA, Platt J, Lee JW, López-Giráldez F, Herbst RS, Koo JS. E2F8 as a Novel Therapeutic Target for Lung Cancer. Journal Of The National Cancer Institute 2015, 107 PMID: 26089541, PMCID: PMC4651101, DOI: 10.1093/jnci/djv151.

Goldberg SB, Herbst RS. From the Guest Editors: Progress and Future Directions for the Treatment of Advanced Lung Cancer. Cancer Journal (Sudbury, Mass.) 2015, 21: 365. PMID: 26389759, DOI: 10.1097/PPO.0000000000000152.

Ferrarotto R, Redman MW, Gandara DR, Herbst RS, Papadimitrakopoulou VA. Lung-MAP--framework, overview, and design principles. Chinese Clinical Oncology 2015, 4: 36. PMID: 26408303, DOI: 10.3978/j.issn.2304-3865.2015.09.02.

Hirsch FR, Herbst RS, Gandara DR. EGFR tyrosine kinase inhibitors in squamous cell lung cancer. The Lancet. Oncology 2015, 16: 872-3. PMID: 26156654, DOI: 10.1016/S1470-2045(15)00126-6.

Skoulidis F, Byers LA, Diao L, Papadimitrakopoulou VA, Tong P, Izzo J, Behrens C, Kadara H, Parra ER, Canales JR, Zhang J, Giri U, Gudikote J, Cortez MA, Yang C, Fan Y, Peyton M, Girard L, Coombes KR, Toniatti C, Heffernan TP, Choi M, Frampton GM, Miller V, Weinstein JN, Herbst RS, Wong KK, Zhang J, Sharma P, Mills GB, Hong WK, Minna JD, Allison JP, Futreal A, Wang J, Wistuba II, Heymach JV. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discovery 2015, 5: 860-77. PMID: 26069186, PMCID: PMC4527963, DOI: 10.1158/2159-8290.CD-14-1236.

Politi K, Herbst RS. Lung cancer in the era of precision medicine. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2015, 21: 2213-20. PMID: 25979927, PMCID: PMC4505624, DOI: 10.1158/1078-0432.CCR-14-2748.

Steuer CE, Papadimitrakopoulou V, Herbst RS, Redman MW, Hirsch FR, Mack PC, Ramalingam SS, Gandara DR. Innovative Clinical Trials: The LUNG-MAP Study. Clinical Pharmacology And Therapeutics 2015, 97: 488-91. PMID: 25676724, DOI: 10.1002/cpt.88.

Morgensztern D, Politi K, Herbst RS. EGFR Mutations in Non-Small-Cell Lung Cancer: Find, Divide, and Conquer. JAMA Oncology 2015, 1: 146-8. PMID: 26181013, DOI: 10.1001/jamaoncol.2014.278.

Herbst RS, Gandara DR, Hirsch FR, Redman MW, LeBlanc M, Mack PC, Schwartz LH, Vokes E, Ramalingam SS, Bradley JD, Sparks D, Zhou Y, Miwa C, Miller VA, Yelensky R, Li Y, Allen JD, Sigal EV, Wholley D, Sigman CC, Blumenthal GM, Malik S, Kelloff GJ, Abrams JS, Blanke CD, Papadimitrakopoulou VA. Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2015, 21: 1514-24. PMID: 25680375, PMCID: PMC4654466, DOI: 10.1158/1078-0432.CCR-13-3473.

Platt A, Morten J, Ji Q, Elvin P, Womack C, Su X, Donald E, Gray N, Read J, Bigley G, Blockley L, Cresswell C, Dale A, Davies A, Zhang T, Fan S, Fu H, Gladwin A, Harrod G, Stevens J, Williams V, Ye Q, Zheng L, de Boer R, Herbst RS, Lee JS, Vasselli J. A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies. BMC Cancer 2015, 15: 171. PMID: 25881079, PMCID: PMC4412099, DOI: 10.1186/s12885-015-1146-8.

Brandon TH, Goniewicz ML, Hanna NH, Hatsukami DK, Herbst RS, Hobin JA, Ostroff JS, Shields PG, Toll BA, Tyne CA, Viswanath K, Warren GW. Electronic nicotine delivery systems: a policy statement from the American Association for Cancer Research and the American Society of Clinical Oncology. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2015, 33: 952-63. PMID: 25572671, DOI: 10.1200/JCO.2014.59.4465.

Schalper KA, Brown J, Carvajal-Hausdorf D, McLaughlin J, Velcheti V, Syrigos KN, Herbst RS, Rimm DL. Objective measurement and clinical significance of TILs in non-small cell lung cancer. Journal Of The National Cancer Institute 2015, 107 PMID: 25650315, PMCID: PMC4565530, DOI: 10.1093/jnci/dju435.

Ma B, Herzog EL, Lee CG, Peng X, Lee CM, Chen X, Rockwell S, Koo JS, Kluger H, Herbst RS, Sznol M, Elias JA. Role of chitinase 3-like-1 and semaphorin 7a in pulmonary melanoma metastasis. Cancer Research 2015, 75: 487-96. PMID: 25511377, PMCID: PMC4321965, DOI: 10.1158/0008-5472.CAN-13-3339.

Brandon TH, Goniewicz ML, Hanna NH, Hatsukami DK, Herbst RS, Hobin JA, Ostroff JS, Shields PG, Toll BA, Tyne CA, Viswanath K, Warren GW. Electronic nicotine delivery systems: a policy statement from the American Association for Cancer Research and the American Society of Clinical Oncology. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2015, 21: 514-25. PMID: 25573384, DOI: 10.1158/1078-0432.CCR-14-2544.

Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, Horn L, Ramalingam SS, Rudin CM, Salgia R, Sequist LV, Shaw AT, Simon GR, Somaiah N, Spigel DR, Wrangle J, Johnson D, Herbst RS, Bunn P, Govindan R. Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer 2015, 10: S1-63. PMID: 25535693, PMCID: PMC4346098, DOI: 10.1097/JTO.0000000000000405.

Lee JW, Park HS, Park SA, Ryu SH, Meng W, Jürgensmeier JM, Kurie JM, Hong WK, Boyer JL, Herbst RS, Koo JS. A Novel Small-Molecule Inhibitor Targeting CREB-CBP Complex Possesses Anti-Cancer Effects along with Cell Cycle Regulation, Autophagy Suppression and Endoplasmic Reticulum Stress. PloS One 2015, 10: e0122628. PMID: 25897662, PMCID: PMC4405579, DOI: 10.1371/journal.pone.0122628.

Henick BS, Herbst RS, Goldberg SB. The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer. Expert Opinion On Therapeutic Targets 2014, 18: 1407-20. PMID: 25331677, DOI: 10.1517/14728222.2014.955794.

Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014, 515: 563-7. PMID: 25428504, PMCID: PMC4836193, DOI: 10.1038/nature14011.

Kris MG, Arenberg DA, Herbst RS, Riely GJ. Emerging science and therapies in non-small-cell lung cancer: targeting the MET pathway. Clinical Lung Cancer 2014, 15: 475. PMID: 25306384, DOI: 10.1016/j.cllc.2014.08.001.

Heymach JV, Lockwood SJ, Herbst RS, Johnson BE, Ryan AJ. EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2014, 25: 1941-1948. PMID: 25057173, PMCID: PMC4176452, DOI: 10.1093/annonc/mdu269.

Massarelli E, Onn A, Marom EM, Alden CM, Liu DD, Tran HT, Mino B, Wistuba II, Faiz SA, Bashoura L, Eapen GA, Morice RC, Jack Lee J, Hong WK, Herbst RS, Jimenez CA. Vandetanib and indwelling pleural catheter for non-small-cell lung cancer with recurrent malignant pleural effusion. Clinical Lung Cancer 2014, 15: 379-86. PMID: 24913066, PMCID: PMC4160385, DOI: 10.1016/j.cllc.2014.04.002.

Hirsch FR, Bunn PA, Herbst RS. "Companion diagnostics": has their time come and gone? Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2014, 20: 4422-4. PMID: 25059519, PMCID: PMC4155019, DOI: 10.1158/1078-0432.CCR-14-0932.

Jürgensmeier JM, Eder JP, Herbst RS. New strategies in personalized medicine for solid tumors: molecular markers and clinical trial designs. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2014, 20: 4425-35. PMID: 25183480, PMCID: PMC5369358, DOI: 10.1158/1078-0432.CCR-13-0753.

Vasan N, Boyer JL, Herbst RS. A RAS renaissance: emerging targeted therapies for KRAS-mutated non-small cell lung cancer. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2014, 20: 3921-30. PMID: 24893629, PMCID: PMC5369356, DOI: 10.1158/1078-0432.CCR-13-1762.

Gettinger S, Herbst RS. B7-H1/PD-1 blockade therapy in non-small cell lung cancer: current status and future direction. Cancer Journal (Sudbury, Mass.) 2014, 20: 281-9. PMID: 25098289, DOI: 10.1097/PPO.0000000000000063.

Ellis LM, Bernstein DS, Voest EE, Berlin JD, Sargent D, Cortazar P, Garrett-Mayer E, Herbst RS, Lilenbaum RC, Sima C, Venook AP, Gonen M, Schilsky RL, Meropol NJ, Schnipper LE. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2014, 32: 1277-80. PMID: 24638016, DOI: 10.1200/JCO.2013.53.8009.

Herbst RS, Hobin JA, Gritz ER. AACR celebrates 50 years of tobacco research and policy. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2014, 20: 1709-18. PMID: 24691637, DOI: 10.1158/1078-0432.CCR-14-0427.

Onn A, Bar J, Herbst RS. Angiogenesis inhibition and lung-cancer therapy. The Lancet. Oncology 2014, 15: 124-5. PMID: 24480554, DOI: 10.1016/S1470-2045(14)70010-5.

Toll BA, Rojewski AM, Duncan LR, Latimer-Cheung AE, Fucito LM, Boyer JL, O'Malley SS, Salovey P, Herbst RS. "Quitting smoking will benefit your health": the evolution of clinician messaging to encourage tobacco cessation. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2014, 20: 301-9. PMID: 24436474, PMCID: PMC3927319, DOI: 10.1158/1078-0432.CCR-13-2261.

Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M, Herbst RS, Gettinger SN, Chen L, Rimm DL. Programmed death ligand-1 expression in non-small cell lung cancer. Laboratory Investigation; A Journal Of Technical Methods And Pathology 2014, 94: 107-16. PMID: 24217091, PMCID: PMC6125250, DOI: 10.1038/labinvest.2013.130.

Balogh EP, Dresler C, Fleury ME, Gritz ER, Kean TJ, Myers ML, Nass SJ, Nevidjon B, Toll BA, Warren GW, Herbst RS. Reducing tobacco-related cancer incidence and mortality: summary of an institute of medicine workshop. The Oncologist 2014, 19: 21-31. PMID: 24304712, PMCID: PMC3903060, DOI: 10.1634/theoncologist.2013-0230.

Blumenschein GR, Saintigny P, Liu S, Kim ES, Tsao AS, Herbst RS, Alden C, Lee JJ, Tang X, Stewart DJ, Kies MS, Fossella FV, Tran HT, Mao L, Hicks ME, Erasmus J, Gupta S, Girard L, Peyton M, Diao L, Wang J, Davis SE, Minna JD, Wistuba I, Hong WK, Heymach JV, Lippman SM. Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2013, 19: 6967-75. PMID: 24166906, PMCID: PMC3905243, DOI: 10.1158/1078-0432.CCR-12-1818.

Kim ES, Moon J, Herbst RS, Redman MW, Dakhil SR, Velasco MR, Hirsch FR, Mack PC, Kelly K, Heymach JV, Gandara DR. Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non-small-cell lung cancer: SWOG S0536. Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer 2013, 8: 1519-28. PMID: 24189513, PMCID: PMC4072123, DOI: 10.1097/JTO.0000000000000009.

Cai G, Wong R, Chhieng D, Levy GH, Gettinger SN, Herbst RS, Puchalski JT, Homer RJ, Hui P. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma. Cancer Cytopathology 2013, 121: 500-7. PMID: 23495083, DOI: 10.1002/cncy.21288.

Warren GW, Marshall JR, Cummings KM, Toll BA, Gritz ER, Hutson A, Dibaj S, Herbst R, Mulshine JL, Hanna N, Dresler CA. Addressing tobacco use in patients with cancer: a survey of American Society of Clinical Oncology members. Journal Of Oncology Practice / American Society Of Clinical Oncology 2013, 9: 258-62. PMID: 23943904, PMCID: PMC3770508, DOI: 10.1200/JOP.2013.001025.

Soria JC, Baselga J, Hanna N, Laurie SA, Bahleda R, Felip E, Calvo E, Armand JP, Shepherd FA, Harbison CT, Berman D, Park JS, Zhang S, Vakkalagadda B, Kurland JF, Pathak AK, Herbst RS. Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours. European Journal Of Cancer (Oxford, England : 1990) 2013, 49: 1815-24. PMID: 23490650, DOI: 10.1016/j.ejca.2013.02.012.

Tsao AS, Liu S, Lee JJ, Alden CM, Blumenschein GR, Herbst R, Davis SE, Kim E, Lippman S, Heymach J, Tran H, Tang X, Wistuba I, Hong WK. Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial. Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer 2013, 8: 658-61. PMID: 23584298, PMCID: PMC5118909, DOI: 10.1097/JTO.0b013e31828d08ae.

Warren GW, Marshall JR, Cummings KM, Toll B, Gritz ER, Hutson A, Dibaj S, Herbst R, Dresler C. Practice patterns and perceptions of thoracic oncology providers on tobacco use and cessation in cancer patients. Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer 2013, 8: 543-8. PMID: 23529191, PMCID: PMC3628367, DOI: 10.1097/JTO.0b013e318288dc96.

Toll BA, Brandon TH, Gritz ER, Warren GW, Herbst RS. Assessing tobacco use by cancer patients and facilitating cessation: an American Association for Cancer Research policy statement. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2013, 19: 1941-8. PMID: 23570694, PMCID: PMC5992896, DOI: 10.1158/1078-0432.CCR-13-0666.

Yamaguchi H, Hsu JL, Chen CT, Wang YN, Hsu MC, Chang SS, Du Y, Ko HW, Herbst R, Hung MC. Caspase-independent cell death is involved in the negative effect of EGF receptor inhibitors on cisplatin in non-small cell lung cancer cells. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2013, 19: 845-54. PMID: 23344263, PMCID: PMC3703145, DOI: 10.1158/1078-0432.CCR-12-2621.

Isobe T, Onn A, Morgensztern D, Jacoby JJ, Wu W, Shintani T, Itasaka S, Shibuya K, Koo PJ, O'Reilly MS, Herbst RS. Evaluation of novel orthotopic nude mouse models for human small-cell lung cancer. Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer 2013, 8: 140-6. PMID: 23328546, DOI: 10.1097/JTO.0b013e3182725ff9.

Saintigny P, Massarelli E, Lin S, Ahn YH, Chen Y, Goswami S, Erez B, O'Reilly MS, Liu D, Lee JJ, Zhang L, Ping Y, Behrens C, Solis Soto LM, Heymach JV, Kim ES, Herbst RS, Lippman SM, Wistuba II, Hong WK, Kurie JM, Koo JS. CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma. Cancer Research 2013, 73: 571-82. PMID: 23204236, PMCID: PMC3548940, DOI: 10.1158/0008-5472.CAN-12-0263.

Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, Nilsson MB, Gudikote J, Tran H, Cardnell RJ, Bearss DJ, Warner SL, Foulks JM, Kanner SB, Gandhi V, Krett N, Rosen ST, Kim ES, Herbst RS, Blumenschein GR, Lee JJ, Lippman SM, Ang KK, Mills GB, Hong WK, Weinstein JN, Wistuba II, Coombes KR, Minna JD, Heymach JV. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2013, 19: 279-90. PMID: 23091115, PMCID: PMC3567921, DOI: 10.1158/1078-0432.CCR-12-1558.

Goldberg SB, Schlessinger J, Boyer JL, Herbst RS. A step towards treating KRAS-mutant NSCLC. The Lancet. Oncology 2013, 14: 3-5. PMID: 23200176, DOI: 10.1016/S1470-2045(12)70528-4.

Morgensztern D, Herbst RS. Miscellaneous agents. Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer 2012, 7: S390-1. PMID: 23160329, DOI: 10.1097/JTO.0b013e31826df1d2.

Ujhazy P, Herbst R. Personalized therapy. Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer 2012, 7: S401-3. PMID: 23160334, DOI: 10.1097/JTO.0b013e31826df27c.

Tsao AS, Liu S, Lee JJ, Alden C, Blumenschein G, Herbst R, Davis SE, Kim E, Lippman S, Stewart D, Tang XM, Wistuba I, Hong WK. Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial. Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer 2012, 7: 1645-52. PMID: 23059780, PMCID: PMC5161038, DOI: 10.1097/JTO.0b013e31826910ff.

Subbiah V, Brown RE, Buryanek J, Trent J, Ashkenazi A, Herbst R, Kurzrock R. Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist. Molecular Cancer Therapeutics 2012, 11: 2541-6. PMID: 22914439, PMCID: PMC3496030, DOI: 10.1158/1535-7163.MCT-12-0358.

Kozloff MF, Martin LP, Krzakowski M, Samuel TA, Rado TA, Arriola E, De Castro Carpeño J, Herbst RS, Tarazi J, Kim S, Rosbrook B, Tortorici M, Olszanski AJ, Cohen RB. Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours. British Journal Of Cancer 2012, 107: 1277-85. PMID: 22990652, PMCID: PMC3494447, DOI: 10.1038/bjc.2012.406.

Martin LP, Kozloff MF, Herbst RS, Samuel TA, Kim S, Rosbrook B, Tortorici M, Chen Y, Tarazi J, Olszanski AJ, Rado T, Starr A, Cohen RB. Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours. British Journal Of Cancer 2012, 107: 1268-76. PMID: 22996612, PMCID: PMC3494424, DOI: 10.1038/bjc.2012.407.

Bosserman L, Prendergast F, Herbst R, Fleisher M, Salom E, Strickland S, Raptis A, Hallquist A, Perree M, Rajurkar S, Karimi M, Rogers K, Davidson D, Willis C, Penalver M, Homesley H, Burrell M, Garrett A, Rutledge J, Chernick M, Presant CA. The microculture-kinetic (MiCK) assay: the role of a drug-induced apoptosis assay in drug development and clinical care. Cancer Research 2012, 72: 3901-5. PMID: 22865459, DOI: 10.1158/0008-5472.CAN-12-0681.

Morgensztern D, Herbst RS. Multitargeted tyrosine kinase inhibitors in unselected patients with advanced non-small-cell lung cancer (NSCLC): impressions from MONET (the motesanib NSCLC efficacy and tolerability study). Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2012, 30: 2805-8. PMID: 22753916, DOI: 10.1200/JCO.2012.42.7260.

Peters EN, Torres E, Toll BA, Cummings KM, Gritz ER, Hyland A, Herbst RS, Marshall JR, Warren GW. Tobacco assessment in actively accruing National Cancer Institute Cooperative Group Program Clinical Trials. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2012, 30: 2869-75. PMID: 22689794, PMCID: PMC3410402, DOI: 10.1200/JCO.2011.40.8815.

Hong DS, Bowles DW, Falchook GS, Messersmith WA, George GC, O'Bryant CL, Vo AC, Klucher K, Herbst RS, Eckhardt SG, Peterson S, Hausman DF, Kurzrock R, Jimeno A. A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2012, 18: 4173-82. PMID: 22693357, DOI: 10.1158/1078-0432.CCR-12-0714.

Redman MW, Crowley JJ, Herbst RS, Hirsch FR, Gandara DR. Design of a phase III clinical trial with prospective biomarker validation: SWOG S0819. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2012, 18: 4004-12. PMID: 22592956, PMCID: PMC3409929, DOI: 10.1158/1078-0432.CCR-12-0167.

Koo PJ, Morgensztern D, Boyer JL, Herbst RS. Targeting vascular endothelial growth factor in patients with squamous cell lung cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2012, 30: 1137-9. PMID: 22355057, DOI: 10.1200/JCO.2011.40.4053.

Takahashi O, Komaki R, Smith PD, Jürgensmeier JM, Ryan A, Bekele BN, Wistuba II, Jacoby JJ, Korshunova MV, Biernacka A, Erez B, Hosho K, Herbst RS, O'Reilly MS. Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2012, 18: 1641-54. PMID: 22275507, PMCID: PMC3306446, DOI: 10.1158/1078-0432.CCR-11-2324.

Gaspar LE, McNamara EJ, Gay EG, Putnam JB, Crawford J, Herbst RS, Bonner JA. Small-cell lung cancer: prognostic factors and changing treatment over 15 years. Clinical Lung Cancer 2012, 13: 115-22. PMID: 22000695, DOI: 10.1016/j.cllc.2011.05.008.

Ihle NT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR, Tsao A, Liu S, Larsen JE, Wang J, Diao L, Coombes KR, Chen L, Zhang S, Abdelmelek MF, Tang X, Papadimitrakopoulou V, Minna JD, Lippman SM, Hong WK, Herbst RS, Wistuba II, Heymach JV, Powis G. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. Journal Of The National Cancer Institute 2012, 104: 228-39. PMID: 22247021, PMCID: PMC3274509, DOI: 10.1093/jnci/djr523.

Berry DA, Herbst RS, Rubin EH. Reports from the 2010 Clinical and Translational Cancer Research Think Tank meeting: design strategies for personalized therapy trials. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2012, 18: 638-44. PMID: 22298897, PMCID: PMC4314693, DOI: 10.1158/1078-0432.CCR-11-2018.

Hirsch FR, Herbst RS. EGFR expression and the flexibility of FLEX. The Lancet. Oncology 2012, 13: 3-5. PMID: 22056020, DOI: 10.1016/S1470-2045(11)70316-3.

Infante JR, Kurzrock R, Spratlin J, Burris HA, Eckhardt SG, Li J, Wu K, Skolnik JM, Hylander-Gans L, Osmukhina A, Huszar D, Herbst RS. A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors. Cancer Chemotherapy And Pharmacology 2012, 69: 165-72. PMID: 21638123, DOI: 10.1007/s00280-011-1667-z.

Pan Y, Xu R, Peach M, Huang CP, Branstetter D, Novotny W, Herbst RS, Eckhardt SG, Holland PM. Evaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours. British Journal Of Cancer 2011, 105: 1830-8. PMID: 22033270, PMCID: PMC3251880, DOI: 10.1038/bjc.2011.456.

Herbst RS. Highlights in NSCLC From the IASLC (International Association for the Study of Lung Cancer) 14th World Conference on Lung Cancer. Clinical Advances In Hematology & Oncology : H&O 2011, 9: 1-24. PMID: 22362179.

Yang F, Tang X, Riquelme E, Behrens C, Nilsson MB, Giri U, Varella-Garcia M, Byers LA, Lin HY, Wang J, Raso MG, Girard L, Coombes K, Lee JJ, Herbst RS, Minna JD, Heymach JV, Wistuba II. Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy. Cancer Research 2011, 71: 5512-21. PMID: 21724587, PMCID: PMC3159530, DOI: 10.1158/0008-5472.CAN-10-2614.

Sandler A, Graham C, Baggstrom M, Herbst R, Zergebel C, Saito K, Jones D. An open-label, multicenter, three-stage, phase II study of s-1 in combination with cisplatin as first-line therapy for patients with advanced non-small cell lung cancer. Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer 2011, 6: 1400-6. PMID: 21673602, DOI: 10.1097/JTO.0b013e31820d7805.

Blumenschein GR, Paulus R, Curran WJ, Robert F, Fossella F, Werner-Wasik M, Herbst RS, Doescher PO, Choy H, Komaki R. Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2011, 29: 2312-8. PMID: 21555682, PMCID: PMC3107747, DOI: 10.1200/JCO.2010.31.7875.

Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR, Tsao A, Stewart DJ, Hicks ME, Erasmus J, Gupta S, Alden CM, Liu S, Tang X, Khuri FR, Tran HT, Johnson BE, Heymach JV, Mao L, Fossella F, Kies MS, Papadimitrakopoulou V, Davis SE, Lippman SM, Hong WK. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discovery 2011, 1: 44-53. PMID: 22586319, PMCID: PMC4211116, DOI: 10.1158/2159-8274.CD-10-0010.

Tran HT, Zinner RG, Blumenschein GR, Oh YW, Papadimitrakopoulou VA, Kim ES, Lu C, Malik M, Lum BL, Herbst RS. Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). Investigational New Drugs 2011, 29: 499-505. PMID: 20094773, DOI: 10.1007/s10637-009-9380-z.

Herbst RS, Ansari R, Bustin F, Flynn P, Hart L, Otterson GA, Vlahovic G, Soh CH, O'Connor P, Hainsworth J. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet 2011, 377: 1846-54. PMID: 21621716, PMCID: PMC4134127, DOI: 10.1016/S0140-6736(11)60545-X.

Govindan R, Morgensztern D, Kommor MD, Herbst RS, Schaefer P, Gandhi J, Saito K, Zergebel C, Schiller J. Phase II trial of S-1 as second-line therapy in patients with advanced non-small cell lung cancer. Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer 2011, 6: 790-5. PMID: 21325974, DOI: 10.1097/JTO.0b013e3182103b51.

Cascone T, Herynk MH, Xu L, Du Z, Kadara H, Nilsson MB, Oborn CJ, Park YY, Erez B, Jacoby JJ, Lee JS, Lin HY, Ciardiello F, Herbst RS, Langley RR, Heymach JV. Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma. The Journal Of Clinical Investigation 2011, 121: 1313-28. PMID: 21436589, PMCID: PMC3070607, DOI: 10.1172/JCI42405.

Wistuba II, Gelovani JG, Jacoby JJ, Davis SE, Herbst RS. Methodological and practical challenges for personalized cancer therapies. Nature Reviews. Clinical Oncology 2011, 8: 135-41. PMID: 21364686, DOI: 10.1038/nrclinonc.2011.2.

Herbst RS, Kurzrock R, Hong DS, Valdivieso M, Hsu CP, Goyal L, Juan G, Hwang YC, Wong S, Hill JS, Friberg G, LoRusso PM. A first-in-human study of conatumumab in adult patients with advanced solid tumors. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2010, 16: 5883-91. PMID: 20947515, DOI: 10.1158/1078-0432.CCR-10-0631.

Chu CT, Jacoby JJ, Herbst RS. Future directions of monoclonal antibody use in personalized lung cancer therapy. Oncology (Williston Park, N.Y.) 2010, 24: 1226-8. PMID: 21192563.

Meng J, Dai B, Fang B, Bekele BN, Bornmann WG, Sun D, Peng Z, Herbst RS, Papadimitrakopoulou V, Minna JD, Peyton M, Roth JA. Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. PloS One 2010, 5: e14124. PMID: 21124782, PMCID: PMC2993951, DOI: 10.1371/journal.pone.0014124.

Herbst RS, Kelly K, Chansky K, Mack PC, Franklin WA, Hirsch FR, Atkins JN, Dakhil SR, Albain KS, Kim ES, Redman M, Crowley JJ, Gandara DR. Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2010, 28: 4747-54. PMID: 20921467, PMCID: PMC3020704, DOI: 10.1200/JCO.2009.27.9356.

Altshuler JS, Balogh E, Barker AD, Eck SL, Friend SH, Ginsburg GS, Herbst RS, Nass SJ, Streeter CM, Wagner JA. Opening up to precompetitive collaboration. Science Translational Medicine 2010, 2: 52cm26. PMID: 20926831, DOI: 10.1126/scitranslmed.3001515.

Carbone DP, Salmon JS, Billheimer D, Chen H, Sandler A, Roder H, Roder J, Tsypin M, Herbst RS, Tsao AS, Tran HT, Dang TP. VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. Lung Cancer (Amsterdam, Netherlands) 2010, 69: 337-40. PMID: 20036440, PMCID: PMC2891357, DOI: 10.1016/j.lungcan.2009.11.019.

Zoog SJ, Ma CY, Kaplan-Lefko PJ, Hawkins JM, Moriguchi J, Zhou L, Pan Y, Hsu CP, Friberg G, Herbst R, Hill J, Juan G. Measurement of conatumumab-induced apoptotic activity in tumors by fine needle aspirate sampling. Cytometry. Part A : The Journal Of The International Society For Analytical Cytology 2010, 77: 849-60. PMID: 20623688, DOI: 10.1002/cyto.a.20940.

Herbst RS, Sun Y, Eberhardt WE, Germonpré P, Saijo N, Zhou C, Wang J, Li L, Kabbinavar F, Ichinose Y, Qin S, Zhang L, Biesma B, Heymach JV, Langmuir P, Kennedy SJ, Tada H, Johnson BE. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. The Lancet. Oncology 2010, 11: 619-26. PMID: 20570559, PMCID: PMC3225192, DOI: 10.1016/S1470-2045(10)70132-7.

Leighl NB, Raez LE, Besse B, Rosen PJ, Barlesi F, Massarelli E, Gabrail N, Hart LL, Albain KS, Berkowitz L, Melnyk O, Shepherd FA, Sternas L, Ackerman J, Shun Z, Miller VA, Herbst RS. A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung. Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer 2010, 5: 1054-9. PMID: 20593550, DOI: 10.1097/jto.0b013e3181e2f7fb.

Jacoby JJ, Erez B, Korshunova MV, Williams RR, Furutani K, Takahashi O, Kirkpatrick L, Lippman SM, Powis G, O'Reilly MS, Herbst RS. Treatment with HIF-1alpha antagonist PX-478 inhibits progression and spread of orthotopic human small cell lung cancer and lung adenocarcinoma in mice. Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer 2010, 5: 940-9. PMID: 20512076, PMCID: PMC3782111, DOI: 10.1097/JTO.0b013e3181dc211f.

Lu C, Lee JJ, Komaki R, Herbst RS, Feng L, Evans WK, Choy H, Desjardins P, Esparaz BT, Truong MT, Saxman S, Kelaghan J, Bleyer A, Fisch MJ. Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial. Journal Of The National Cancer Institute 2010, 102: 859-65. PMID: 20505152, PMCID: PMC2902826, DOI: 10.1093/jnci/djq179.

Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O'Dwyer PJ, Gordon MS, Novotny W, Goldwasser MA, Tohnya TM, Lum BL, Ashkenazi A, Jubb AM, Mendelson DS. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2010, 28: 2839-46. PMID: 20458040, DOI: 10.1200/JCO.2009.25.1991.

Haura EB, Camidge DR, Reckamp K, Chiappori A, Johnson F, Herbst R, Wong K, Carbone D. Molecular origins of lung cancer: prospects for personalized prevention and therapy. Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer 2010, 5: S207-13. PMID: 20502275, DOI: 10.1097/JTO.0b013e3181e2f682.

Viswanath K, Herbst RS, Land SR, Leischow SJ, Shields PG. Tobacco and cancer: an American Association for Cancer Research policy statement. Cancer Research 2010, 70: 3419-30. PMID: 20388799, DOI: 10.1158/0008-5472.CAN-10-1087.

William WN, Khuri FR, Fossella FV, Glisson BS, Zinner RG, Lee JJ, Herbst RS, Lippman SM, Kim ES. Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small-cell lung cancer as frontline and second-line therapy. American Journal Of Clinical Oncology 2010, 33: 148-52. PMID: 19687727, PMCID: PMC5118944, DOI: 10.1097/COC.0b013e318199fb99.

Gandara DR, Mack PC, Li T, Lara PN, Herbst RS. [Evolving treatment algorithms for advanced non-small-cell lung cancer: 2009 looking toward 2012]. Zhongguo Fei Ai Za Zhi = Chinese Journal Of Lung Cancer 2010, 13: 238-41. PMID: 20681067, PMCID: PMC6136060, DOI: 10.3779/j.issn.1009-3419.2010.03.16.

Zinner RG, Novello S, Peng G, Herbst R, Obasaju C, Scagliotti G. Comparison of patient outcomes according to histology among pemetrexed-treated patients with stage IIIB/IV non-small-cell lung cancer in two phase II trials. Clinical Lung Cancer 2010, 11: 126-31. PMID: 20199979, DOI: 10.3816/CLC.2010.n.017.

Meuillet EJ, Zuohe S, Lemos R, Ihle N, Kingston J, Watkins R, Moses SA, Zhang S, Du-Cuny L, Herbst R, Jacoby JJ, Zhou LL, Ahad AM, Mash EA, Kirkpatrick DL, Powis G. Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor. Molecular Cancer Therapeutics 2010, 9: 706-17. PMID: 20197390, PMCID: PMC2837366, DOI: 10.1158/1535-7163.MCT-09-0985.

Camidge DR, Herbst RS, Gordon MS, Eckhardt SG, Kurzrock R, Durbin B, Ing J, Tohnya TM, Sager J, Ashkenazi A, Bray G, Mendelson D. A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2010, 16: 1256-63. PMID: 20145186, DOI: 10.1158/1078-0432.CCR-09-1267.

Tsao AS, Roth JA, Herbst RS. Surgery: Future directions in multimodality therapy for NSCLC. Nature Reviews. Clinical Oncology 2010, 7: 10-2. PMID: 20029443, DOI: 10.1038/nrclinonc.2009.174.

Gandara DR, Mack PC, Li T, Lara PN, Herbst RS. Evolving treatment algorithms for advanced non-small-cell lung cancer: 2009 looking toward 2012. Clinical Lung Cancer 2009, 10: 392-4. PMID: 19900855, DOI: 10.3816/CLC.2009.n.074.

Bar J, Herbst RS, Onn A. Targeted drug delivery strategies to treat lung metastasis. Expert Opinion On Drug Delivery 2009, 6: 1003-16. PMID: 19663628, DOI: 10.1517/17425240903167926.

Pao W, Kris MG, Iafrate AJ, Ladanyi M, Jänne PA, Wistuba II, Miake-Lye R, Herbst RS, Carbone DP, Johnson BE, Lynch TJ. Integration of molecular profiling into the lung cancer clinic. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2009, 15: 5317-22. PMID: 19706816, DOI: 10.1158/1078-0432.CCR-09-0913.

Herbst RS, Hong D, Chap L, Kurzrock R, Jackson E, Silverman JM, Rasmussen E, Sun YN, Zhong D, Hwang YC, Evelhoch JL, Oliner JD, Le N, Rosen LS. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2009, 27: 3557-65. PMID: 19546406, DOI: 10.1200/JCO.2008.19.6683.

Camidge R, Gaspar L, Goss G, Kelly K, Ramalingam S, Reckamp K, Simon G, Tsao M, West HJ, Herbst R, Johnson D, Bunn P, Govindan R. Summary of selected presentations from the 8th annual targeted therapy in lung cancer symposium. Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer 2009, 4: 930-5. PMID: 19550249, DOI: 10.1097/JTO.0b013e3181a9a03b.

Salmon S, Chen H, Chen S, Herbst R, Tsao A, Tran H, Sandler A, Billheimer D, Shyr Y, Lee JW, Massion P, Brahmer J, Schiller J, Carbone D, Dang TP. Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimen. Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer 2009, 4: 689-96. PMID: 19404214, PMCID: PMC3563261, DOI: 10.1097/JTO.0b013e3181a526b3.

Hanrahan EO, Ryan AJ, Mann H, Kennedy SJ, Langmuir P, Natale RB, Herbst RS, Johnson BE, Heymach JV. Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2009, 15: 3600-9. PMID: 19447868, DOI: 10.1158/1078-0432.CCR-08-2568.

Herbst RS, Hirsch FR. Patient selection criteria and the FLEX Study. Lancet 2009, 373: 1497-8. PMID: 19410696, DOI: 10.1016/S0140-6736(09)60834-5.

Ng CS, Kodama Y, Mullani NA, Barron BJ, Wei W, Herbst RS, Abbruzzese JL, Charnsangavej C. Tumor blood flow measured by perfusion computed tomography and 15O-labeled water positron emission tomography: a comparison study. Journal Of Computer Assisted Tomography 2009, 33: 460-5. PMID: 19478644, DOI: 10.1097/RCT.0b013e318182d2e0.

Kim ES, Mauer AM, William WN, Tran HT, Liu D, Lee JJ, Windt P, Hong WK, Vokes EE, Herbst RS. A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer. Cancer 2009, 115: 1713-22. PMID: 19208430, PMCID: PMC5142442, DOI: 10.1002/cncr.24148.

Craft BS, Kurzrock R, Lei X, Herbst R, Lippman S, Fu S, Karp DD. The changing face of phase 1 cancer clinical trials: new challenges in study requirements. Cancer 2009, 115: 1592-7. PMID: 19165808, PMCID: PMC2668727, DOI: 10.1002/cncr.24171.

William WN, Kim ES, Herbst RS. Cetuximab therapy for patients with advanced squamous cell carcinomas of the head and neck. Nature Clinical Practice. Oncology 2009, 6: 132-3. PMID: 19190590, DOI: 10.1038/ncponc1321.

Giaccone G, Iacona RB, Fandi A, Janas M, Ochs JS, Herbst RS, Johnson DH. Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy. Journal Of Cancer Research And Clinical Oncology 2009, 135: 467-76. PMID: 18787840, DOI: 10.1007/s00432-008-0466-3.

Herbst RS, Lynch TJ, Sandler AB. Beyond doublet chemotherapy for advanced non-small-cell lung cancer: combination of targeted agents with first-line chemotherapy. Clinical Lung Cancer 2009, 10: 20-7. PMID: 19289368, DOI: 10.3816/CLC.2009.n.003.

Zinner RG, Komaki R, Cox JD, Glisson BS, Pisters KM, Herbst RS, Kies M, Liao Z, Hong WK, Fossella FV. Dose escalation of gemcitabine is possible with concurrent chest three-dimensional rather than two-dimensional radiotherapy: a phase I trial in patients with stage III non-small-cell lung cancer. International Journal Of Radiation Oncology, Biology, Physics 2009, 73: 119-27. PMID: 18556142, DOI: 10.1016/j.ijrobp.2008.03.069.

Rice D, Swisher S, Pisters K, Fossella F, Herbst R, Hofstetter W, Kies M, Komaki R, Lippman S, Mehran R, Roth J, Stewart D, Vaporciyan A, Walsh G, Cox J. Comment on "Treatment of non-small cell lung cancer stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition)". Chest 2008, 134: 1349. PMID: 19059972, DOI: 10.1378/chest.08-0655.

Heymach JV, Paz-Ares L, De Braud F, Sebastian M, Stewart DJ, Eberhardt WE, Ranade AA, Cohen G, Trigo JM, Sandler AB, Bonomi PD, Herbst RS, Krebs AD, Vasselli J, Johnson BE. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2008, 26: 5407-15. PMID: 18936474, DOI: 10.1200/JCO.2008.17.3138.

Herbst RS, Sandler A. Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC. The Oncologist 2008, 13: 1166-76. PMID: 18997180, DOI: 10.1634/theoncologist.2008-0108.

Herbst RS, Heymach JV, Lippman SM. Lung cancer. The New England Journal Of Medicine 2008, 359: 1367-80. PMID: 18815398, DOI: 10.1056/NEJMra0802714.

Hirsch FR, Herbst RS, Olsen C, Chansky K, Crowley J, Kelly K, Franklin WA, Bunn PA, Varella-Garcia M, Gandara DR. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2008, 26: 3351-7. PMID: 18612151, PMCID: PMC3368372, DOI: 10.1200/JCO.2007.14.0111.

Vermorken JB, Herbst RS, Leon X, Amellal N, Baselga J. Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies. Cancer 2008, 112: 2710-9. PMID: 18481809, DOI: 10.1002/cncr.23442.

Ashkenazi A, Herbst RS. To kill a tumor cell: the potential of proapoptotic receptor agonists. The Journal Of Clinical Investigation 2008, 118: 1979-90. PMID: 18523647, PMCID: PMC2396896, DOI: 10.1172/JCI34359.

Einhorn LH, Bonomi P, Bunn PA, Camidge DR, Carbone DP, Choy H, Dubinett SM, Gandara DR, Gaspar LE, Govindan R, Johnson DH, Minna JD, Scagliotti G, West HJ, Herbst RS. Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer. Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer 2008, 3: 545-55. PMID: 18449013, PMCID: PMC3374724, DOI: 10.1097/JTO.0b013e318170627f.

Mullani NA, Herbst RS, O'Neil RG, Gould KL, Barron BJ, Abbruzzese JL. Tumor blood flow measured by PET dynamic imaging of first-pass 18F-FDG uptake: a comparison with 15O-labeled water-measured blood flow. Journal Of Nuclear Medicine : Official Publication, Society Of Nuclear Medicine 2008, 49: 517-23. PMID: 18344436, DOI: 10.2967/jnumed.107.048504.

Marom EM, Martinez CH, Truong MT, Lei X, Sabloff BS, Munden RF, Gladish GW, Herbst RS, Morice RC, Stewart DJ, Jimenez CA, Blumenschein GR, Onn A. Tumor cavitation during therapy with antiangiogenesis agents in patients with lung cancer. Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer 2008, 3: 351-7. PMID: 18379352, DOI: 10.1097/JTO.0b013e318168c7e9.

Miller VA, Riely GJ, Zakowski MF, Li AR, Patel JD, Heelan RT, Kris MG, Sandler AB, Carbone DP, Tsao A, Herbst RS, Heller G, Ladanyi M, Pao W, Johnson DH. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2008, 26: 1472-8. PMID: 18349398, DOI: 10.1200/JCO.2007.13.0062.

Oh Y, Herbst RS, Burris H, Cleverly A, Musib L, Lahn M, Bepler G. Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2008, 26: 1135-41. PMID: 18309949, DOI: 10.1200/JCO.2007.14.3685.

Herbst RS. Current and future strategies for antiangiogenic agents in non-small-cell lung cancer. Clinical Lung Cancer 2008, 9 Suppl 2: S50. PMID: 21884998, DOI: 10.3816/CLC.2008.s.007.

Herbst RS. Bevacizumab/chemotherapy in non-small-cell lung cancer: looking for a few good men? Clinical Lung Cancer 2008, 9: 75-6. PMID: 18501092, DOI: 10.3816/CLC.2008.n.011.

Zhou X, Liu S, Kim ES, Herbst RS, Lee JJ. Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine. Clinical Trials (London, England) 2008, 5: 181-93. PMID: 18559407, PMCID: PMC5481999, DOI: 10.1177/1740774508091815.

Bar J, Herbst RS, Onn A. Multitargeted inhibitors in lung cancer: new clinical data. Clinical Lung Cancer 2008, 9 Suppl 3: S92-9. PMID: 19419930, DOI: 10.3816/CLC.2008.s.014.

Shibuya K, Komaki R, Shintani T, Itasaka S, Ryan A, Jürgensmeier JM, Milas L, Ang K, Herbst RS, O'Reilly MS. Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer. International Journal Of Radiation Oncology, Biology, Physics 2007, 69: 1534-43. PMID: 17889445, PMCID: PMC2151850, DOI: 10.1016/j.ijrobp.2007.07.2350.

Herbst RS, O'Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, Hart L, Melnyk O, Ramies D, Lin M, Sandler A. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2007, 25: 4743-50. PMID: 17909199, DOI: 10.1200/JCO.2007.12.3026.

Herbst RS, Davies AM, Natale RB, Dang TP, Schiller JH, Garland LL, Miller VA, Mendelson D, Van den Abbeele AD, Melenevsky Y, de Vries DJ, Eberhard DA, Lyons B, Lutzker SG, Johnson BE. Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2007, 13: 6175-81. PMID: 17947484, DOI: 10.1158/1078-0432.CCR-07-0460.

Wu W, O'Reilly MS, Langley RR, Tsan RZ, Baker CH, Bekele N, Tang XM, Onn A, Fidler IJ, Herbst RS. Expression of epidermal growth factor (EGF)/transforming growth factor-alpha by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice. Molecular Cancer Therapeutics 2007, 6: 2652-63. PMID: 17913856, DOI: 10.1158/1535-7163.MCT-06-0759.

Heymach JV, Johnson BE, Prager D, Csada E, Roubec J, Pesek M, Spásová I, Belani CP, Bodrogi I, Gadgeel S, Kennedy SJ, Hou J, Herbst RS. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2007, 25: 4270-7. PMID: 17878479, DOI: 10.1200/JCO.2006.10.5122.

Lynch TJ, Bonomi PD, Butts C, Davies AM, Engelman J, Govindan R, Herbst RS, Heymach JV, Johnson BE, Martins RG, Perez-Soler R, Riely GJ, Sandler AB, Sequist LV, Socinski MA, Wong KK, Hart CS. Novel agents in the treatment of lung cancer: Fourth Cambridge Conference. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2007, 13: s4583-8. PMID: 17671145, DOI: 10.1158/1078-0432.CCR-07-0716.

Herbst RS, Oh Y, Wagle A, Lahn M. Enzastaurin, a protein kinase Cbeta- selective inhibitor, and its potential application as an anticancer agent in lung cancer. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2007, 13: s4641-6. PMID: 17671157, DOI: 10.1158/1078-0432.CCR-07-0538.

Cohen MZ, Slomka J, Pentz RD, Flamm AL, Gold D, Herbst RS, Abbruzzese JL. Phase I participants' views of quality of life and trial participation burdens. Supportive Care In Cancer : Official Journal Of The Multinational Association Of Supportive Care In Cancer 2007, 15: 885-90. PMID: 17252219, DOI: 10.1007/s00520-007-0216-0.

Huang EH, Liao Z, Cox JD, Guerrero TM, Chang JY, Jeter M, Borghero Y, Wei X, Fossella F, Herbst RS, Blumenschein GR, Moran C, Allen PK, Komaki R. Comparison of outcomes for patients with unresectable, locally advanced non-small-cell lung cancer treated with induction chemotherapy followed by concurrent chemoradiation vs. concurrent chemoradiation alone. International Journal Of Radiation Oncology, Biology, Physics 2007, 68: 779-85. PMID: 17418967, DOI: 10.1016/j.ijrobp.2007.01.002.

Pentz RD, Flamm AL, Sugarman J, Cohen MZ, Xu Z, Herbst RS, Abbruzzese JL. Who should go first in trials with scarce agents? The views of potential participants. IRB 2007, 29: 1-6. PMID: 17847620.

Rosen LS, Kurzrock R, Mulay M, Van Vugt A, Purdom M, Ng C, Silverman J, Koutsoukos A, Sun YN, Bass MB, Xu RY, Polverino A, Wiezorek JS, Chang DD, Benjamin R, Herbst RS. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2007, 25: 2369-76. PMID: 17557949, DOI: 10.1200/JCO.2006.07.8170.

Onn A, Herbst RS. Angiogenesis and lung cancer: implications for prognosis and treatment. The Lancet. Oncology 2007, 8: 460-1. PMID: 17540301, DOI: 10.1016/S1470-2045(07)70153-5.

Massarelli E, Varella-Garcia M, Tang X, Xavier AC, Ozburn NC, Liu DD, Bekele BN, Herbst RS, Wistuba II. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2007, 13: 2890-6. PMID: 17504988, DOI: 10.1158/1078-0432.CCR-06-3043.

Itasaka S, Komaki R, Herbst RS, Shibuya K, Shintani T, Hunter NR, Onn A, Bucana CD, Milas L, Ang KK, O'Reilly MS. Endostatin improves radioresponse and blocks tumor revascularization after radiation therapy for A431 xenografts in mice. International Journal Of Radiation Oncology, Biology, Physics 2007, 67: 870-8. PMID: 17293237, PMCID: PMC1976280, DOI: 10.1016/j.ijrobp.2006.10.030.

Wu W, Onn A, Isobe T, Itasaka S, Langley RR, Shitani T, Shibuya K, Komaki R, Ryan AJ, Fidler IJ, Herbst RS, O'Reilly MS. Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. Molecular Cancer Therapeutics 2007, 6: 471-83. PMID: 17308046, DOI: 10.1158/1535-7163.MCT-06-0416.

Herbst RS, Heymach JV, O'Reilly MS, Onn A, Ryan AJ. Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opinion On Investigational Drugs 2007, 16: 239-49. PMID: 17243944, DOI: 10.1517/13543784.16.2.239.

Herbst RS, Lippman SM. Molecular signatures of lung cancer--toward personalized therapy. The New England Journal Of Medicine 2007, 356: 76-8. PMID: 17202459, DOI: 10.1056/NEJMe068218.

Ozols RF, Herbst RS, Colson YL, Gralow J, Bonner J, Curran WJ, Eisenberg BL, Ganz PA, Kramer BS, Kris MG, Markman M, Mayer RJ, Raghavan D, Reaman GH, Sawaya R, Schilsky RL, Schuchter LM, Sweetenham JW, Vahdat LT, Winn RJ. Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2007, 25: 146-62. PMID: 17158528, DOI: 10.1200/JCO.2006.09.7030.

Herbst RS. Toxicities of antiangiogenic therapy in non-small-cell lung cancer. Clinical Lung Cancer 2006, 8 Suppl 1: S23-30. PMID: 17239287, DOI: 10.3816/clc.2006.s.010.

Oh SH, Lee OH, Schroeder CP, Oh YW, Ke S, Cha HJ, Park RW, Onn A, Herbst RS, Li C, Lee HY. Antimetastatic activity of insulin-like growth factor binding protein-3 in lung cancer is mediated by insulin-like growth factor-independent urokinase-type plasminogen activator inhibition. Molecular Cancer Therapeutics 2006, 5: 2685-95. PMID: 17121915, DOI: 10.1158/1535-7163.MCT-06-0142.

Herbst RS. Therapeutic options to target angiogenesis in human malignancies. Expert Opinion On Emerging Drugs 2006, 11: 635-50. PMID: 17064223, DOI: 10.1517/14728214.11.4.635.

Vokes E, Herbst R, Sandler A. Angiogenesis inhibition in the treatment of lung cancer. Clinical Advances In Hematology & Oncology : H&O 2006, 4: 1-10; quiz 11-2. PMID: 17143257.

Carducci MA, Musib L, Kies MS, Pili R, Truong M, Brahmer JR, Cole P, Sullivan R, Riddle J, Schmidt J, Enas N, Sinha V, Thornton DE, Herbst RS. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2006, 24: 4092-9. PMID: 16943527, DOI: 10.1200/JCO.2005.05.3447.

Govindan R, Natale R, Wade J, Herbst R, Krebs A, Reiling R, Hensing T, Wozniak A, Belani CP, Kelly K, Ochs J. Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program. Lung Cancer (Amsterdam, Netherlands) 2006, 53: 331-7. PMID: 16797779, DOI: 10.1016/j.lungcan.2006.04.013.

Legin AV, Kirsanov DO, Babain VA, Borovoy AV, Herbst RS. Cross-sensitive rare-earth metal sensors based on bidentate neutral organophosphorus compounds and chlorinated cobalt dicarbollide. Analytica Chimica Acta 2006, 572: 243-7. PMID: 17723484, DOI: 10.1016/j.aca.2006.03.115.

Sandler A, Herbst R. Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2006, 12: 4421s-4425s. PMID: 16857821, DOI: 10.1158/1078-0432.CCR-06-0796.

Heymach JV, Nilsson M, Blumenschein G, Papadimitrakopoulou V, Herbst R. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2006, 12: 4441s-4445s. PMID: 16857825, DOI: 10.1158/1078-0432.CCR-06-0286.

Green LJ, Marder P, Ray C, Cook CA, Jaken S, Musib LC, Herbst RS, Carducci M, Britten CD, Basche M, Eckhardt SG, Thornton D. Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitor. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2006, 12: 3408-15. PMID: 16740765, DOI: 10.1158/1078-0432.CCR-05-2231.

Thomas SK, Fossella FV, Liu D, Schaerer R, Tsao AS, Kies MS, Pisters KM, Blumenschein GR, Glisson BS, Lee JJ, Herbst RS, Zinner RG. Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program. Clinical Lung Cancer 2006, 7: 326-31. PMID: 16640804, DOI: 10.3816/CLC.2006.n.014.

Massarelli E, Herbst RS. Use of novel second-line targeted therapies in non-small cell lung cancer. Seminars In Oncology 2006, 33: S9-16. PMID: 16472704, DOI: 10.1053/j.seminoncol.2005.12.007.

Herbst RS, Bajorin DF, Bleiberg H, Blum D, Hao D, Johnson BE, Ozols RF, Demetri GD, Ganz PA, Kris MG, Levin B, Markman M, Raghavan D, Reaman GH, Sawaya R, Schuchter LM, Sweetenham JW, Vahdat LT, Vokes EE, Winn RJ, Mayer RJ. Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2006, 24: 190-205. PMID: 16326753, DOI: 10.1200/JCO.2005.04.8678.

Robert F, Blumenschein G, Herbst RS, Fossella FV, Tseng J, Saleh MN, Needle M. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2005, 23: 9089-96. PMID: 16301597, DOI: 10.1200/JCO.2004.00.1438.

Fujimoto N, Wislez M, Zhang J, Iwanaga K, Dackor J, Hanna AE, Kalyankrishna S, Cody DD, Price RE, Sato M, Shay JW, Minna JD, Peyton M, Tang X, Massarelli E, Herbst R, Threadgill DW, Wistuba II, Kurie JM. High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor. Cancer Research 2005, 65: 11478-85. PMID: 16357156, DOI: 10.1158/0008-5472.CAN-05-1977.

Gandara DR, Vallières E, Gaspar LE, Kelly K, Albain KS, Herbst RS, Lara PN, Mack P, Gumerlock PH, Crowley JJ. Therapeutic strategies for combined-modality therapy of locally advanced non-small-cell lung cancer: rationale for consolidation docetaxel therapy. Clinical Lung Cancer 2005, 7 Suppl 3: S93-7. PMID: 16384543, DOI: 10.3816/clc.2005.s.017.

Zinner RG, Fossella FV, Gladish GW, Glisson BS, Blumenschein GR, Papadimitrakopoulou VA, Pisters KM, Kim ES, Oh YW, Peeples BO, Ye Z, Curiel RE, Obasaju CK, Hong WK, Herbst RS. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer 2005, 104: 2449-56. PMID: 16258975, DOI: 10.1002/cncr.21480.

Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW, Sgroi DC, Muir B, Riemenschneider MJ, Iacona RB, Krebs AD, Johnson DH, Giaccone G, Herbst RS, Manegold C, Fukuoka M, Kris MG, Baselga J, Ochs JS, Haber DA. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2005, 23: 8081-92. PMID: 16204011, DOI: 10.1200/JCO.2005.02.7078.

Onn A, Herbst RS. Molecular targeted therapy for lung cancer. Lancet 2005, 366: 1507-8. PMID: 16257327, DOI: 10.1016/S0140-6736(05)67608-8.

Onn A, Choe DH, Herbst RS, Correa AM, Munden RF, Truong MT, Vaporciyan AA, Isobe T, Gilcrease MZ, Marom EM. Tumor cavitation in stage I non-small cell lung cancer: epidermal growth factor receptor expression and prediction of poor outcome. Radiology 2005, 237: 342-7. PMID: 16183941, DOI: 10.1148/radiol.2371041650.

Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, Ince WL, Jänne PA, Januario T, Johnson DH, Klein P, Miller VA, Ostland MA, Ramies DA, Sebisanovic D, Stinson JA, Zhang YR, Seshagiri S, Hillan KJ. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2005, 23: 5900-9. PMID: 16043828, DOI: 10.1200/JCO.2005.02.857.

Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, Ramies D, Johnson DH, Miller VA. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2005, 23: 5892-9. PMID: 16043829, DOI: 10.1200/JCO.2005.02.840.

Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, Pithavala YK, Reich SD, Freddo JL, Wilding G. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2005, 23: 5474-83. PMID: 16027439, DOI: 10.1200/JCO.2005.04.192.

Liu G, Rugo HS, Wilding G, McShane TM, Evelhoch JL, Ng C, Jackson E, Kelcz F, Yeh BM, Lee FT, Charnsangavej C, Park JW, Ashton EA, Steinfeldt HM, Pithavala YK, Reich SD, Herbst RS. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2005, 23: 5464-73. PMID: 16027440, DOI: 10.1200/JCO.2005.04.143.

Herbst RS, Arquette M, Shin DM, Dicke K, Vokes EE, Azarnia N, Hong WK, Kies MS. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2005, 23: 5578-87. PMID: 16009949, DOI: 10.1200/JCO.2005.07.120.

Herbst RS. Role of novel targeted therapies in the clinic. British Journal Of Cancer 2005, 92 Suppl 1: S21-7. PMID: 15928655, PMCID: PMC2362061, DOI: 10.1038/sj.bjc.6602605.

Onn A, Herbst RS. What is the best way to manage patients treated with gefitinib for non-small-cell lung cancer? Nature Clinical Practice. Oncology 2005, 2: 290-1. PMID: 16264983, DOI: 10.1038/ncponc0191.

Isobe T, Herbst RS, Onn A. Current management of advanced non-small cell lung cancer: targeted therapy. Seminars In Oncology 2005, 32: 315-28. PMID: 15988686, DOI: 10.1053/j.seminoncol.2005.02.016.

Herbst RS, Onn A, Sandler A. Angiogenesis and lung cancer: prognostic and therapeutic implications. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2005, 23: 3243-56. PMID: 15886312, DOI: 10.1200/JCO.2005.18.853.

Cella D, Herbst RS, Lynch TJ, Prager D, Belani CP, Schiller JH, Heyes A, Ochs JS, Wolf MK, Kay AC, Kris MG, Natale RB. Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2005, 23: 2946-54. PMID: 15699477, DOI: 10.1200/JCO.2005.05.153.

Gaspar LE, Gay EG, Crawford J, Putnam JB, Herbst RS, Bonner JA. Limited-stage small-cell lung cancer (stages I-III): observations from the National Cancer Data Base. Clinical Lung Cancer 2005, 6: 355-60. PMID: 15943896, DOI: 10.3816/CLC.2005.n.015.

Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, Blumenschein G, Lee JJ, Liu DD, Truong MT, Hong WK, Tran H, Tsao A, Xie D, Ramies DA, Mass R, Seshagiri S, Eberhard DA, Kelley SK, Sandler A. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2005, 23: 2544-55. PMID: 15753462, DOI: 10.1200/JCO.2005.02.477.

Sasaki R, Komaki R, Macapinlac H, Erasmus J, Allen P, Forster K, Putnam JB, Herbst RS, Moran CA, Podoloff DA, Roth JA, Cox JD. [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2005, 23: 1136-43. PMID: 15718309, DOI: 10.1200/JCO.2005.06.129.

Herbst RS. Erlotinib. Clinical Advances In Hematology & Oncology : H&O 2005, 3: 125, 141. PMID: 16166980.

Davis DW, Takamori R, Raut CP, Xiong HQ, Herbst RS, Stadler WM, Heymach JV, Demetri GD, Rashid A, Shen Y, Wen S, Abbruzzese JL, McConkey DJ. Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2005, 11: 678-89. PMID: 15701856.

Herbst RS, LoRusso P, Isobe T, Hurwitz HI. Angiogenesis pathway inhibitors. Cancer Chemotherapy And Biological Response Modifiers 2005, 22: 225-45. PMID: 16110614, DOI: 10.1016/s0921-4410(04)22010-5.

Onn A, Isobe T, Wu W, Itasaka S, Shintani T, Shibuya K, Kenji Y, O'reilly MS, Fidler IJ, Herbst RS. Epidermal growth factor receptor tyrosine kinase inhibitor does not improve paclitaxel effect in an orthotopic mouse model of lung cancer. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2004, 10: 8613-9. PMID: 15623645, DOI: 10.1158/1078-0432.CCR-04-1241.

Herbst RS, Fukuoka M, Baselga J. Gefitinib--a novel targeted approach to treating cancer. Nature Reviews. Cancer 2004, 4: 956-65. PMID: 15573117, DOI: 10.1038/nrc1506.

Herbst RS, Sandler AB. Overview of the current status of human epidermal growth factor receptor inhibitors in lung cancer. Clinical Lung Cancer 2004, 6 Suppl 1: S7-S19. PMID: 15638959, DOI: 10.3816/clc.2004.s.009.

Xiong HQ, Herbst R, Faria SC, Scholz C, Davis D, Jackson EF, Madden T, McConkey D, Hicks M, Hess K, Charnsangavej CA, Abbruzzese JL. A phase I surrogate endpoint study of SU6668 in patients with solid tumors. Investigational New Drugs 2004, 22: 459-66. PMID: 15292716, DOI: 10.1023/B:DRUG.0000036688.96453.8d.

Gridelli C, Massarelli E, Maione P, Rossi A, Herbst RS, Onn A, Ciardiello F. Potential role of molecularly targeted therapy in the management of advanced nonsmall cell lung carcinoma in the elderly. Cancer 2004, 101: 1733-44. PMID: 15386339, DOI: 10.1002/cncr.20572.

Tran HT, Blumenschein GR, Lu C, Meyers CA, Papadimitrakopoulou V, Fossella FV, Zinner R, Madden T, Smythe LG, Puduvalli VK, Munden R, Truong M, Herbst RS. Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors. Cancer Chemotherapy And Pharmacology 2004, 54: 308-14. PMID: 15184994, DOI: 10.1007/s00280-004-0816-z.

Herbst RS. EGFR inhibition in NSCLC: the emerging role of cetuximab. Journal Of The National Comprehensive Cancer Network : JNCCN 2004, 2 Suppl 2: S41-51. PMID: 19780245.

Zinner RG, Fossella FV, Herbst RS. Pemetrexed in advanced NSCLC: a review of the clinical data. Oncology (Williston Park, N.Y.) 2004, 18: 54-62. PMID: 15339061.

Lynch TJ, Adjei AA, Bunn PA, DuBois RN, Gandara DR, Giaccone G, Govindan R, Herbst RS, Johnson BE, Khuri FR, Perez-Soler R, Rosell R, Rowinsky EK, Sandler AB, Scagliotti GV, Schiller JH, Shapiro GI, Socinski MA, Hart CS. Novel agents in the treatment of lung cancer: conference summary statement. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2004, 10: 4199s-4204s. PMID: 15217958, DOI: 10.1158/1078-0432.CCR-040021.

Sandler AB, Johnson DH, Herbst RS. Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2004, 10: 4258s-4262s. PMID: 15217970, DOI: 10.1158/1078-0432.CCR-040023.

Herbst RS, Frankel SR. Oblimersen sodium (Genasense bcl-2 antisense oligonucleotide): a rational therapeutic to enhance apoptosis in therapy of lung cancer. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2004, 10: 4245s-4248s. PMID: 15217967, DOI: 10.1158/1078-0432.CCR-040018.

Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2004, 22: 2184-91. PMID: 15169807, DOI: 10.1200/JCO.2004.11.022.

Khuri FR, Glisson BS, Kim ES, Statkevich P, Thall PF, Meyers ML, Herbst RS, Munden RF, Tendler C, Zhu Y, Bangert S, Thompson E, Lu C, Wang XM, Shin DM, Kies MS, Papadimitrakopoulou V, Fossella FV, Kirschmeier P, Bishop WR, Hong WK. Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2004, 10: 2968-76. PMID: 15131032, DOI: 10.1158/1078-0432.ccr-03-0412.

Herbst RS. Imaging in drug development. Clinical Advances In Hematology & Oncology : H&O 2004, 2: 268-9. PMID: 16163191.

Komaki R, Lee JS, Milas L, Lee HK, Fossella FV, Herbst RS, Allen PK, Liao Z, Stevens CW, Lu C, Zinner RG, Papadimitrakopoulou VA, Kies MS, Blumenschein GR, Pisters KM, Glisson BS, Kurie J, Kaplan B, Garza VP, Mooring D, Tucker SL, Cox JD. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. International Journal Of Radiation Oncology, Biology, Physics 2004, 58: 1369-77. PMID: 15050312, DOI: 10.1016/j.ijrobp.2003.10.005.

Zinner RG, Herbst RS. Pemetrexed in the treatment of advanced non-small-cell lung cancer: a review of the clinical data. Clinical Lung Cancer 2004, 5 Suppl 2: S67-74. PMID: 15117428, DOI: 10.3816/clc.2004.s.006.

Zinner RG, Glisson BS, Fossella FV, Pisters KM, Kies MS, Lee PM, Massarelli E, Sabloff B, Fritsche HA, Ro JY, Ordonez NG, Tran HT, Yang Y, Smith TL, Mass RD, Herbst RS. Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease. Lung Cancer (Amsterdam, Netherlands) 2004, 44: 99-110. PMID: 15013588, DOI: 10.1016/j.lungcan.2003.09.026.

McDonald DM, Teicher BA, Stetler-Stevenson W, Ng SS, Figg WD, Folkman J, Hanahan D, Auerbach R, O'Reilly M, Herbst R, Cheresh D, Gordon M, Eggermont A, Libutti SK. Report from the society for biological therapy and vascular biology faculty of the NCI workshop on angiogenesis monitoring. Journal Of Immunotherapy (Hagerstown, Md. : 1997) 2004, 27: 161-75. PMID: 14770088, DOI: 10.1097/00002371-200403000-00010.

Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MK, Rennie P, Fandi A, Johnson DH. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2004, 22: 777-84. PMID: 14990632, DOI: 10.1200/JCO.2004.08.001.

Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2004, 22: 785-94. PMID: 14990633, DOI: 10.1200/JCO.2004.07.215.

Davis DW, Shen Y, Mullani NA, Wen S, Herbst RS, O'Reilly M, Abbruzzese JL, McConkey DJ. Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin in primary human tumors. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2004, 10: 33-42. PMID: 14734449, DOI: 10.1158/1078-0432.ccr-0736-3.

Herbst RS, Sandler AB. Non-small cell lung cancer and antiangiogenic therapy: what can be expected of bevacizumab? The Oncologist 2004, 9 Suppl 1: 19-26. PMID: 15178812, DOI: 10.1634/theoncologist.9-suppl_1-19.

Herbst RS. Review of epidermal growth factor receptor biology. International Journal Of Radiation Oncology, Biology, Physics 2004, 59: 21-6. PMID: 15142631, DOI: 10.1016/j.ijrobp.2003.11.041.

Onn A, Correa AM, Gilcrease M, Isobe T, Massarelli E, Bucana CD, O'Reilly MS, Hong WK, Fidler IJ, Putnam JB, Herbst RS. Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2004, 10: 136-43. PMID: 14734462, DOI: 10.1158/1078-0432.ccr-0373-3.

Herbst RS, Bunn PA. Targeting the epidermal growth factor receptor in non-small cell lung cancer. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2003, 9: 5813-24. PMID: 14676101.

Onn A, Isobe T, Itasaka S, Wu W, O'Reilly MS, Ki Hong W, Fidler IJ, Herbst RS. Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2003, 9: 5532-9. PMID: 14654533.

Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003, 290: 2149-58. PMID: 14570950, DOI: 10.1001/jama.290.16.2149.

Herbst RS, Khuri FR. Mode of action of docetaxel - a basis for combination with novel anticancer agents. Cancer Treatment Reviews 2003, 29: 407-15. PMID: 12972359, DOI: 10.1016/s0305-7372(03)00097-5.

Herbst RS, Hammond LA, Carbone DP, Tran HT, Holroyd KJ, Desai A, Williams JI, Bekele BN, Hait H, Allgood V, Solomon S, Schiller JH. A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2003, 9: 4108-15. PMID: 14519633.

Herbst RS, O'Reilly MS. The rationale and potential of combining novel biologic therapies with radiotherapy: focus on non-small cell lung cancer. Seminars In Oncology 2003, 30: 113-23. PMID: 12908142, DOI: 10.1016/s0093-7754(03)00269-0.

Herbst RS, Kies MS. Gefitinib: current and future status in cancer therapy. Clinical Advances In Hematology & Oncology : H&O 2003, 1: 466-72. PMID: 16258434.

Davis DW, McConkey DJ, Abbruzzese JL, Herbst RS. Surrogate markers in antiangiogenesis clinical trials. British Journal Of Cancer 2003, 89: 8-14. PMID: 12838293, PMCID: PMC2394225, DOI: 10.1038/sj.bjc.6601035.

Erasmus JJ, Gladish GW, Broemeling L, Sabloff BS, Truong MT, Herbst RS, Munden RF. Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2003, 21: 2574-82. PMID: 12829678, DOI: 10.1200/JCO.2003.01.144.

Herbst RS. Erlotinib (Tarceva): an update on the clinical trial program. Seminars In Oncology 2003, 30: 34-46. PMID: 12840799.

LoRusso PM, Herbst RS, Rischin D, Ranson M, Calvert H, Raymond E, Kieback D, Kaye S, Gianni L, Harris A, Bjork T, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Feyereislova A, Heyes A, Averbuch SD, Ochs J, Baselga J. Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2003, 9: 2040-8. PMID: 12796366.

Herbst RS, LoRusso PM, Purdom M, Ward D. Dermatologic side effects associated with gefitinib therapy: clinical experience and management. Clinical Lung Cancer 2003, 4: 366-9. PMID: 14599302, DOI: 10.3816/clc.2003.n.016.

Davis DW, McConkey DJ, Zhang W, Herbst RS. Antiangiogenic tumor therapy. BioTechniques 2003, 34: 1048-50, 1052, 1054 passim. PMID: 12765031, DOI: 10.2144/03345dd01.

Wirth LJ, Lucca J, Ostler P, Fidias P, Lynch C, Jänne PA, Herbst RS, Johnson BE, Sugarbaker DJ, Mathisen DJ, Lukanich JM, Choi NC, Berman SM, Skarin AT. Induction docetaxel and carboplatin followed by weekly docetaxel and carboplatin with concurrent radiotherapy, then surgery in stage III non-small cell lung cancer: a Phase I study. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2003, 9: 1698-704. PMID: 12738723.

Herbst RS. Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients. Seminars In Oncology 2003, 30: 30-8. PMID: 12644982, DOI: 10.1053/sonc.2003.50030.

Herbst RS, Onn A, Mendelsohn J. The role of growth factor signaling in malignancy. Cancer Treatment And Research 2003, 115: 19-72. PMID: 12613192, DOI: 10.1007/0-306-48158-8_2.

Yano S, Herbst RS, Sone S. In vitro and in vivo assays for the proliferative and vascular permeabilization activities of vascular endothelial growth factor (VEGF) and its receptor. Methods In Molecular Medicine 2003, 74: 391-8. PMID: 12415710, DOI: 10.1385/1-59259-323-2:391.

Blumenschein GR, Herbst RS. Integration of targeted therapies in gemcitabine chemotherapy regimens. Clinical Lung Cancer 2003, 4: 217-23. PMID: 14624709, DOI: 10.3816/clc.2003.n.001.

Swisher SG, Roth JA, Komaki R, Gu J, Lee JJ, Hicks M, Ro JY, Hong WK, Merritt JA, Ahrar K, Atkinson NE, Correa AM, Dolormente M, Dreiling L, El-Naggar AK, Fossella F, Francisco R, Glisson B, Grammer S, Herbst R, Huaringa A, Kemp B, Khuri FR, Kurie JM, Liao Z, McDonnell TJ, Morice R, Morello F, Munden R, Papadimitrakopoulou V, Pisters KM, Putnam JB, Sarabia AJ, Shelton T, Stevens C, Shin DM, Smythe WR, Vaporciyan AA, Walsh GL, Yin M. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2003, 9: 93-101. PMID: 12538456.

Massarelli E, Andre F, Liu DD, Lee JJ, Wolf M, Fandi A, Ochs J, Le Chevalier T, Fossella F, Herbst RS. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer (Amsterdam, Netherlands) 2003, 39: 55-61. PMID: 12499095, DOI: 10.1016/s0169-5002(02)00308-2.

Onn A, Herbst RS. Angiogenesis, metastasis, and lung cancer. An overview. Methods In Molecular Medicine 2003, 74: 329-48. PMID: 12415706, DOI: 10.1385/1-59259-323-2:329.

Herbst RS, Madden TL, Tran HT, Blumenschein GR, Meyers CA, Seabrooke LF, Khuri FR, Puduvalli VK, Allgood V, Fritsche HA, Hinton L, Newman RA, Crane EA, Fossella FV, Dordal M, Goodin T, Hong WK. Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2002, 20: 4440-7. PMID: 12431966, DOI: 10.1200/JCO.2002.04.006.

Herbst RS, Hong WK. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer. Seminars In Oncology 2002, 29: 18-30. PMID: 12422310, DOI: 10.1053/sonc.2002.35644.

Kaban K, Herbst RS. Angiogenesis as a target for cancer therapy. Hematology/oncology Clinics Of North America 2002, 16: 1125-71. PMID: 12512387, DOI: 10.1016/s0889-8588(02)00047-3.

Herbst RS, Mullani NA, Davis DW, Hess KR, McConkey DJ, Charnsangavej C, O'Reilly MS, Kim HW, Baker C, Roach J, Ellis LM, Rashid A, Pluda J, Bucana C, Madden TL, Tran HT, Abbruzzese JL. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2002, 20: 3804-14. PMID: 12228200, DOI: 10.1200/JCO.2002.05.102.

Herbst RS, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Baselga J, Rojo F, Hong WK, Swaisland H, Averbuch SD, Ochs J, LoRusso PM. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2002, 20: 3815-25. PMID: 12228201, DOI: 10.1200/JCO.2002.03.038.

Herbst RS, Hess KR, Tran HT, Tseng JE, Mullani NA, Charnsangavej C, Madden T, Davis DW, McConkey DJ, O'Reilly MS, Ellis LM, Pluda J, Hong WK, Abbruzzese JL. Phase I study of recombinant human endostatin in patients with advanced solid tumors. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2002, 20: 3792-803. PMID: 12228199, DOI: 10.1200/JCO.2002.11.061.

Pentz RD, Flamm AL, Sugarman J, Cohen MZ, Daniel Ayers G, Herbst RS, Abbruzzese JL. Study of the media's potential influence on prospective research participants' understanding of and motivations for participation in a high-profile phase I trial. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2002, 20: 3785-91. PMID: 12228198, DOI: 10.1200/JCO.2002.04.084.

Herbst RS. Targeted therapy in non-small-cell lung cancer. Oncology (Williston Park, N.Y.) 2002, 16: 19-24. PMID: 12375797.

Herbst RS, Khuri FR, Lu C, Liu DD, Fossella FV, Glisson BS, Pisters KM, Shin DM, Papadimitrakopoulou VA, Kurie JM, Blumenschein G, Kies MS, Zinner R, Jung MS, Lu R, Lee JJ, Munden RF, Hong WK, Lee JS. The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy. Cancer 2002, 95: 340-53. PMID: 12124835, DOI: 10.1002/cncr.10629.

Kim ES, Herbst RS. Angiogenesis inhibitors in lung cancer. Current Oncology Reports 2002, 4: 325-33. PMID: 12044242, DOI: 10.1007/s11912-002-0008-0.

Zinner RG, Kim J, Herbst RS. Non-small cell lung cancer clinical trials with trastuzumab: their foundation and preliminary results. Lung Cancer (Amsterdam, Netherlands) 2002, 37: 17-27. PMID: 12057863, DOI: 10.1016/s0169-5002(02)00035-1.

Herbst RS. ZD1839: targeting the epidermal growth factor receptor in cancer therapy. Expert Opinion On Investigational Drugs 2002, 11: 837-49. PMID: 12036427, DOI: 10.1517/13543784.11.6.837.

Fan D, Yano S, Shinohara H, Solorzano C, Van Arsdall M, Bucana CD, Pathak S, Kruzel E, Herbst RS, Onn A, Roach JS, Onda M, Wang QC, Pastan I, Fidler IJ. Targeted therapy against human lung cancer in nude mice by high-affinity recombinant antimesothelin single-chain Fv immunotoxin. Molecular Cancer Therapeutics 2002, 1: 595-600. PMID: 12479219.

Waxman ES, Herbst RS. The role of the epidermal growth factor receptor in the treatment of colorectal carcinoma. Seminars In Oncology Nursing 2002, 18: 20-9. PMID: 12053861, DOI: 10.1053/sonu.2002.33072.

Kim ES, Kies M, Herbst RS. Novel therapeutics for head and neck cancer. Current Opinion In Oncology 2002, 14: 334-42. PMID: 11981281, DOI: 10.1097/00001622-200205000-00014.

Yang DJ, Kim KD, Schechter NR, Yu DF, Wu P, Azhdarinia A, Roach JS, Kalimi SK, Ozaki K, Fogler WE, Bryant JL, Herbst R, Abbruzzes J, Kim EE, Podoloff DA. Assessment of antiangiogenic effect using 99mTc-EC-endostatin. Cancer Biotherapy & Radiopharmaceuticals 2002, 17: 233-45. PMID: 12030117, DOI: 10.1089/108497802753773856.

Herbst RS. Targeted therapy using novel agents in the treatment of non-small-cell lung cancer. Clinical Lung Cancer 2002, 3 Suppl 1: S30-8. PMID: 14720353, DOI: 10.3816/clc.2002.s.006.

Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 2002, 94: 1593-611. PMID: 11920518, DOI: 10.1002/cncr.10372.

Herbst RS, Langer CJ. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Seminars In Oncology 2002, 29: 27-36. PMID: 11894011, DOI: 10.1053/sonc.2002.31525.

Herbst RS, Hidalgo M, Pierson AS, Holden SN, Bergen M, Eckhardt SG. Angiogenesis inhibitors in clinical development for lung cancer. Seminars In Oncology 2002, 29: 66-77. PMID: 11894016, DOI: 10.1053/sonc.2002.31527.

Massarelli E, Onn A, Zinner R, Khuri FR, Kim ES, Herbst RS. New targets for the treatment of advanced non-small cell lung cancer. Cancer Chemotherapy And Biological Response Modifiers 2002, 20: 717-61. PMID: 12703232.

Herbst RS, Kies MS. ZD1839 (Iressa) in non-small cell lung cancer. The Oncologist 2002, 7 Suppl 4: 9-15. PMID: 12202783, DOI: 10.1634/theoncologist.7-suppl_4-9.

Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R, LoRusso P, Rischin D, Sauleda S, Gee J, Nicholson RI, Baselga J. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2002, 20: 110-24. PMID: 11773160, DOI: 10.1200/JCO.2002.20.1.110.

Kim ES, Lu C, Khuri FR, Tonda M, Glisson BS, Liu D, Jung M, Hong WK, Herbst RS. A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands) 2001, 34: 427-32. PMID: 11714540, DOI: 10.1016/s0169-5002(01)00278-1.

Kim ES, Khuri FR, Herbst RS. Epidermal growth factor receptor biology (IMC-C225). Current Opinion In Oncology 2001, 13: 506-13. PMID: 11673692, DOI: 10.1097/00001622-200111000-00014.

Onn A, Tseng JE, Herbst RS. Thalidomide, cyclooxygenase-2, and angiogenesis: potential for therapy. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2001, 7: 3311-3. PMID: 11705841.

Tseng JE, Glisson BS, Khuri FR, Shin DM, Myers JN, El-Naggar AK, Roach JS, Ginsberg LE, Thall PF, Wang X, Teddy S, Lawhorn KN, Zentgraf RE, Steinhaus GD, Pluda JM, Abbruzzese JL, Hong WK, Herbst RS. Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer 2001, 92: 2364-73. PMID: 11745292, DOI: 10.1002/1097-0142(20011101)92:9<2364::aid-cncr1584>3.0.co;2-p.

Herbst RS, Lynch C, Vasconcelles M, Teicher BA, Strauss G, Elias A, Anderson I, Zacarola P, Dang NH, Leong T, Salgia R, Skarin AT. Gemcitabine and vinorelbine in patients with advanced lung cancer: preclinical studies and report of a phase I trial. Cancer Chemotherapy And Pharmacology 2001, 48: 151-9. PMID: 11561781, DOI: 10.1007/s002800100282.

Herbst RS, Khuri FR, Fossella FV, Glisson BS, Kies MS, Pisters KM, Riddle JR, Terry KA, Lee JS. ZD1839 (Iressa) in non-small-cell lung cancer. Clinical Lung Cancer 2001, 3: 27-32. PMID: 14656386, DOI: 10.3816/clc.2001.n.014.

Herbst RS, Kim ES, Harari PM. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer. Expert Opinion On Biological Therapy 2001, 1: 719-32. PMID: 11727507, DOI: 10.1517/14712598.1.4.719.

Khuri FR, Herbst RS, Fossella FV. Emerging therapies in non-small-cell lung cancer. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2001, 12: 739-44. PMID: 11484947, DOI: 10.1023/a:1011197500223.

Skarin AT, Herbst RS, Leong TL, Bailey A, Sugarbaker D. Lung cancer in patients under age 40. Lung Cancer (Amsterdam, Netherlands) 2001, 32: 255-64. PMID: 11390007, DOI: 10.1016/s0169-5002(00)00233-6.

Herbst RS, Lee AT, Tran HT, Abbruzzese JL. Clinical studies of angiogenesis inhibitors: the University of Texas MD Anderson Center Trial of Human Endostatin. Current Oncology Reports 2001, 3: 131-40. PMID: 11177745, DOI: 10.1007/s11912-001-0013-8.

Herbst RS, Fidler IJ. Angiogenesis and lung cancer: potential for therapy. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2000, 6: 4604-6. PMID: 11156208.

Yano S, Shinohara H, Herbst RS, Kuniyasu H, Bucana CD, Ellis LM, Fidler IJ. Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. The American Journal Of Pathology 2000, 157: 1893-903. PMID: 11106562, PMCID: PMC1885766, DOI: 10.1016/S0002-9440(10)64828-6.

Lilenbaum RC, Herbst RS. Vinorelbine and gemcitabine combinations in advanced non small-cell lung cancer. Clinical Lung Cancer 2000, 2: 123-7. PMID: 14731322, DOI: 10.3816/clc.2000.n.024.

Yano S, Shinohara H, Herbst RS, Kuniyasu H, Bucana CD, Ellis LM, Davis DW, McConkey DJ, Fidler IJ. Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis. Cancer Research 2000, 60: 4959-67. PMID: 10987313.

Herbst RS, Yano S, Kuniyasu H, Khuri FR, Bucana CD, Guo F, Liu D, Kemp B, Lee JJ, Hong WK, Fidler IJ. Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2000, 6: 790-7. PMID: 10741698.

Yano S, Herbst RS, Shinohara H, Knighton B, Bucana CD, Killion JJ, Wood J, Fidler IJ. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2000, 6: 957-65. PMID: 10741721.

Herbst RS, Lilenbaum R. Gemcitabine and vinorelbine combinations in the treatment of non-small cell lung cancer. Seminars In Oncology 1999, 26: 67-70; discussion 71-2. PMID: 10585011.

Teicher BA, Williams JI, Takeuchi H, Ara G, Herbst RS, Buxton D. Potential of the aminosterol, squalamine in combination therapy in the rat 13,762 mammary carcinoma and the murine Lewis lung carcinoma. Anticancer Research 1998, 18: 2567-73. PMID: 9703911.

Teicher BA, Ara G, Keyes SR, Herbst RS, Frei E. Acute in vivo resistance in high-dose therapy. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 1998, 4: 483-91. PMID: 9516940.

Herbst RS, Takeuchi H, Teicher BA. Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models. Cancer Chemotherapy And Pharmacology 1998, 41: 497-504. PMID: 9554595, DOI: 10.1007/s002800050773.

Wen PY, Alyea EP, Simon D, Herbst RS, Soiffer RJ, Antin JH. Guillain-Barré syndrome following allogeneic bone marrow transplantation. Neurology 1997, 49: 1711-4. PMID: 9409375, DOI: 10.1212/wnl.49.6.1711.

Teicher BA, Kakeji Y, Ara G, Herbst RS, Northey D. Prostate carcinoma response to cytotoxic therapy: in vivo resistance. In Vivo (Athens, Greece) 1997, 11: 453-61. PMID: 9509295.

Teicher BA, Ikebe M, Ara G, Keyes SR, Herbst RS. Transforming growth factor-beta 1 overexpression produces drug resistance in vivo: reversal by decorin. In Vivo (Athens, Greece) 1997, 11: 463-72. PMID: 9509296.

Herbst RS, Dang NH, Skarin AT. Chemotherapy for advanced non-small cell lung cancer. Hematology/oncology Clinics Of North America 1997, 11: 473-517. PMID: 9209907, DOI: 10.1016/s0889-8588(05)70445-7.

Herbst RS, Nielsch U, Sladek F, Lai E, Babiss LE, Darnell JE. Differential regulation of hepatocyte-enriched transcription factors explains changes in albumin and transthyretin gene expression among hepatoma cells. The New Biologist 1991, 3: 289-96. PMID: 1878351.

Herbst RS, Boczko EM, Darnell JE, Babiss LE. The mouse albumin enhancer contains a negative regulatory element that interacts with a novel DNA-binding protein. Molecular And Cellular Biology 1990, 10: 3896-905. PMID: 2370857, PMCID: PMC360900, DOI: 10.1128/mcb.10.8.3896-3905.1990.

Herbst RS, Pelletier M, Boczko EM, Babiss LE. The state of cellular differentiation determines the activity of the adenovirus E1A enhancer element: evidence for negative regulation of enhancer function. Journal Of Virology 1990, 64: 161-72. PMID: 2136708, PMCID: PMC249075, DOI: 10.1128/JVI.64.1.161-172.1990.

Herbst RS, Pelletier M, Babiss LE. Cis effect of the type 5 adenovirus E1A gene enhancer element on cellular transformation. Journal Of Cellular Biochemistry 1990, 42: 33-44. PMID: 2137130, DOI: 10.1002/jcb.240420104.

Herbst RS, Friedman N, Darnell JE, Babiss LE. Positive and negative regulatory elements in the mouse albumin enhancer. Proceedings Of The National Academy Of Sciences Of The United States Of America 1989, 86: 1553-7. PMID: 2922398, PMCID: PMC286736, DOI: 10.1073/pnas.86.5.1553.

Herbst RS, Hermo H, Fisher PB, Babiss LE. Regulation of adenovirus and cellular gene expression and of cellular transformation by the E1B-encoded 175-amino-acid protein. Journal Of Virology 1988, 62: 4634-43. PMID: 2972843, PMCID: PMC253576, DOI: 10.1128/JVI.62.12.4634-4643.1988.

Babiss LE, Herbst RS, Bennett AL, Darnell JE. Factors that interact with the rat albumin promoter are present both in hepatocytes and other cell types. Genes & Development 1987, 1: 256-67. PMID: 3678823, DOI: 10.1101/gad.1.3.256.

van den Pol AN, Herbst RS, Powell JF. Tyrosine hydroxylase-immunoreactive neurons of the hypothalamus: a light and electron microscopic study. Neuroscience 1984, 13: 1117-56. PMID: 6152034, DOI: 10.1016/0306-4522(84)90292-6.